[
  {
    "bcr_patient_uuid": "BE6531B2-D1F3-44AB-9C02-1CEAE51EF2BB",
    "patient_ID": "TCGA.3M.AB46",
    "bcr_drug_barcode": "TCGA-3M-AB46-D62340",
    "bcr_drug_uuid": "A8A6E33A-7DF9-466B-ABD0-F8EB912CAA9E",
    "form_completion_date": "2014-7-15",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 92,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 212,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BE6531B2-D1F3-44AB-9C02-1CEAE51EF2BB",
    "patient_ID": "TCGA.3M.AB46",
    "bcr_drug_barcode": "TCGA-3M-AB46-D62341",
    "bcr_drug_uuid": "68A96028-7241-4576-BEF3-522FB06F918D",
    "form_completion_date": "2014-7-15",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 92,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 212,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "85C11B74-9E50-4DA1-8C0B-D5677CC801B1",
    "patient_ID": "TCGA.3M.AB47",
    "bcr_drug_barcode": "TCGA-3M-AB47-D62414",
    "bcr_drug_uuid": "7085FF17-B2F6-4379-A52C-02E0AE0D3FF8",
    "form_completion_date": "2014-7-16",
    "pharmaceutical_therapy_drug_name": "5-FU",
    "days_to_drug_start": 122,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 242,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "85C11B74-9E50-4DA1-8C0B-D5677CC801B1",
    "patient_ID": "TCGA.3M.AB47",
    "bcr_drug_barcode": "TCGA-3M-AB47-D62415",
    "bcr_drug_uuid": "0E179CDF-639A-4865-8C10-D026B21350A7",
    "form_completion_date": "2014-7-16",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 122,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 153,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "85C11B74-9E50-4DA1-8C0B-D5677CC801B1",
    "patient_ID": "TCGA.3M.AB47",
    "bcr_drug_barcode": "TCGA-3M-AB47-D63806",
    "bcr_drug_uuid": "232467AA-D9FE-4745-9752-0D4468BA22B3",
    "form_completion_date": "2014-8-19",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 181,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 242,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "85C11B74-9E50-4DA1-8C0B-D5677CC801B1",
    "patient_ID": "TCGA.3M.AB47",
    "bcr_drug_barcode": "TCGA-3M-AB47-D63807",
    "bcr_drug_uuid": "BD0300F3-3F28-4175-B3A5-66933FBA9BA7",
    "form_completion_date": "2014-8-19",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 122,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 153,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "85C11B74-9E50-4DA1-8C0B-D5677CC801B1",
    "patient_ID": "TCGA.3M.AB47",
    "bcr_drug_barcode": "TCGA-3M-AB47-D63808",
    "bcr_drug_uuid": "B51C6EE9-22F5-4866-B30E-63C380B27504",
    "form_completion_date": "2014-8-19",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 181,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 242,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "4310A287-5F01-4E0D-94E3-96C5379C3245",
    "patient_ID": "TCGA.B7.A5TI",
    "bcr_drug_barcode": "TCGA-B7-A5TI-D68105",
    "bcr_drug_uuid": "3D445D2E-4D6C-4F38-816D-11557D91CB96",
    "form_completion_date": "2014-11-13",
    "pharmaceutical_therapy_drug_name": "ELOXATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 10,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 231,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4ED55013-3853-48EA-909F-7D26D5055637",
    "patient_ID": "TCGA.B7.A5TK",
    "bcr_drug_barcode": "TCGA-B7-A5TK-D68108",
    "bcr_drug_uuid": "21DF9812-CE12-45E9-8ED5-D0783ABD6A21",
    "form_completion_date": "2014-11-13",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 13,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 55,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "77535AF0-DEF4-439C-B50D-8720712235DD",
    "patient_ID": "TCGA.B7.A5TN",
    "bcr_drug_barcode": "TCGA-B7-A5TN-D68110",
    "bcr_drug_uuid": "044E255F-164A-423E-A529-BE16C9D53E72",
    "form_completion_date": "2014-11-13",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 23,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 166,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "74f859cf-6df5-4e96-ae6b-cfaab691d5fd",
    "patient_ID": "TCGA.BR.4191",
    "bcr_drug_barcode": "TCGA-BR-4191-D21832",
    "bcr_drug_uuid": "FB0CF767-1C09-4947-A54C-0430D365B7DB",
    "form_completion_date": "2012-2-21",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 3,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 104,
    "drug_cycles": 4,
    "drug_units": "MG/M2",
    "drug_tota_dose_units": "MG/M2",
    "drug_dose": 75,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 300
  },
  {
    "bcr_patient_uuid": "74f859cf-6df5-4e96-ae6b-cfaab691d5fd",
    "patient_ID": "TCGA.BR.4191",
    "bcr_drug_barcode": "TCGA-BR-4191-D34867",
    "bcr_drug_uuid": "F094AE2F-D6F4-4A3B-AB37-50384861F5F7",
    "form_completion_date": "2012-9-5",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 3,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 104,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "74f859cf-6df5-4e96-ae6b-cfaab691d5fd",
    "patient_ID": "TCGA.BR.4191",
    "bcr_drug_barcode": "TCGA-BR-4191-D34868",
    "bcr_drug_uuid": "C0185AF6-78AF-4986-AAE1-4CE1614B5E41",
    "form_completion_date": "2012-9-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 3,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 104,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8520654b-2192-46cf-9d72-1ddb885a7c55",
    "patient_ID": "TCGA.BR.4201",
    "bcr_drug_barcode": "TCGA-BR-4201-D21839",
    "bcr_drug_uuid": "5BB6E54D-DF0D-4D35-87E3-3E90423A6224",
    "form_completion_date": "2012-2-21",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 21,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 137,
    "drug_cycles": 3,
    "drug_units": "MG/M2",
    "drug_tota_dose_units": "MG/M2",
    "drug_dose": 75,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 225
  },
  {
    "bcr_patient_uuid": "8520654b-2192-46cf-9d72-1ddb885a7c55",
    "patient_ID": "TCGA.BR.4201",
    "bcr_drug_barcode": "TCGA-BR-4201-D33387",
    "bcr_drug_uuid": "550C74E7-B697-4F1B-B06D-454E119ABAAE",
    "form_completion_date": "2012-6-29",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 21,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 137,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "117eb38b-0c62-4336-a866-fa5bd013256a",
    "patient_ID": "TCGA.BR.4279",
    "bcr_drug_barcode": "TCGA-BR-4279-D28739",
    "bcr_drug_uuid": "B5657D71-90E2-4C17-BC26-67252AFE9687",
    "form_completion_date": "2012-2-29",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 27,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 115,
    "drug_cycles": 3,
    "drug_units": "MG/M2/DAY",
    "drug_tota_dose_units": "MG/M2/DAY",
    "drug_dose": 400,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 1200
  },
  {
    "bcr_patient_uuid": "117eb38b-0c62-4336-a866-fa5bd013256a",
    "patient_ID": "TCGA.BR.4279",
    "bcr_drug_barcode": "TCGA-BR-4279-D28736",
    "bcr_drug_uuid": "B9FA89E8-EABF-40BC-BA99-A5C8C3998E1B",
    "form_completion_date": "2012-2-29",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 27,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 115,
    "drug_cycles": 3,
    "drug_units": "MG/M2",
    "drug_tota_dose_units": "MG/M2",
    "drug_dose": 40,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 120
  },
  {
    "bcr_patient_uuid": "117eb38b-0c62-4336-a866-fa5bd013256a",
    "patient_ID": "TCGA.BR.4279",
    "bcr_drug_barcode": "TCGA-BR-4279-D28738",
    "bcr_drug_uuid": "0AE895CA-CC2E-4609-9227-679397E29B30",
    "form_completion_date": "2012-2-29",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 27,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 115,
    "drug_cycles": 3,
    "drug_units": "MG/M2",
    "drug_tota_dose_units": "MG/M2",
    "drug_dose": 400,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 1200
  },
  {
    "bcr_patient_uuid": "117eb38b-0c62-4336-a866-fa5bd013256a",
    "patient_ID": "TCGA.BR.4279",
    "bcr_drug_barcode": "TCGA-BR-4279-D28737",
    "bcr_drug_uuid": "6DAA089B-8DBA-47DB-8389-9B6902193F22",
    "form_completion_date": "2012-2-29",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 27,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 115,
    "drug_cycles": 3,
    "drug_units": "MG/M2",
    "drug_tota_dose_units": "MG/M2",
    "drug_dose": 40,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 120
  },
  {
    "bcr_patient_uuid": "75a29059-4705-4a55-bc3d-f5923b24b358",
    "patient_ID": "TCGA.BR.6455",
    "bcr_drug_barcode": "TCGA-BR-6455-D29820",
    "bcr_drug_uuid": "17B02BF2-584F-439C-9C5C-86CE0B01449E",
    "form_completion_date": "2012-3-29",
    "pharmaceutical_therapy_drug_name": "ETOPOSIDE PHOSPHATE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 44,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 131,
    "drug_cycles": 3,
    "drug_units": "MG/DAY",
    "drug_tota_dose_units": "MG",
    "drug_dose": 200,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 1800
  },
  {
    "bcr_patient_uuid": "75a29059-4705-4a55-bc3d-f5923b24b358",
    "patient_ID": "TCGA.BR.6455",
    "bcr_drug_barcode": "TCGA-BR-6455-D29821",
    "bcr_drug_uuid": "D67276A0-F271-4D63-BA0F-EED534691DB5",
    "form_completion_date": "2012-3-29",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 44,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 131,
    "drug_cycles": 3,
    "drug_units": "MG/DAY",
    "drug_tota_dose_units": "MG",
    "drug_dose": 750,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 6750
  },
  {
    "bcr_patient_uuid": "75a29059-4705-4a55-bc3d-f5923b24b358",
    "patient_ID": "TCGA.BR.6455",
    "bcr_drug_barcode": "TCGA-BR-6455-D29822",
    "bcr_drug_uuid": "382E9A61-0E25-4BF8-82DD-860295903BCE",
    "form_completion_date": "2012-3-29",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 44,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 131,
    "drug_cycles": 3,
    "pharma_type_other": "ANCILLARY",
    "drug_units": "MG/DAY",
    "drug_tota_dose_units": "MG",
    "drug_dose": 100,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 900
  },
  {
    "bcr_patient_uuid": "05ce16d4-a999-491a-91ad-9449a57228ff",
    "patient_ID": "TCGA.BR.6457",
    "bcr_drug_barcode": "TCGA-BR-6457-D30817",
    "bcr_drug_uuid": "20F9746C-645D-4ABD-ADC4-8BACE2E1BBAB",
    "form_completion_date": "2012-4-17",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 126,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "05ce16d4-a999-491a-91ad-9449a57228ff",
    "patient_ID": "TCGA.BR.6457",
    "bcr_drug_barcode": "TCGA-BR-6457-D30818",
    "bcr_drug_uuid": "0E8A2B84-2A74-4A66-8F9D-CB2C1DC6D95B",
    "form_completion_date": "2012-4-17",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 126,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "e516880b-c4e5-43cd-a358-be0db88564d7",
    "patient_ID": "TCGA.BR.6458",
    "bcr_drug_barcode": "TCGA-BR-6458-D30862",
    "bcr_drug_uuid": "329B1450-1CBA-4CF7-A0A2-F6EA2E19F46C",
    "form_completion_date": "2012-4-17",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 58,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 167,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "e516880b-c4e5-43cd-a358-be0db88564d7",
    "patient_ID": "TCGA.BR.6458",
    "bcr_drug_barcode": "TCGA-BR-6458-D30863",
    "bcr_drug_uuid": "2CE0589D-6B0E-40B9-98B7-8CDD365F4C80",
    "form_completion_date": "2012-4-17",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 58,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 167,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "e516880b-c4e5-43cd-a358-be0db88564d7",
    "patient_ID": "TCGA.BR.6458",
    "bcr_drug_barcode": "TCGA-BR-6458-D30864",
    "bcr_drug_uuid": "843BC274-766C-438D-8603-FD34A0DD704A",
    "form_completion_date": "2012-4-17",
    "pharmaceutical_therapy_drug_name": "ETOPOSIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 58,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 98,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "9d7305be-60a3-4ecf-856a-bd5321166590",
    "patient_ID": "TCGA.BR.6563",
    "bcr_drug_barcode": "TCGA-BR-6563-D40649",
    "bcr_drug_uuid": "CF9D5B5A-E824-42E3-83D0-12C88C7F9F78",
    "form_completion_date": "2013-2-26",
    "pharmaceutical_therapy_drug_name": "DOXORUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 157,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 330,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "9d7305be-60a3-4ecf-856a-bd5321166590",
    "patient_ID": "TCGA.BR.6563",
    "bcr_drug_barcode": "TCGA-BR-6563-D40651",
    "bcr_drug_uuid": "85F8652E-5C14-44F8-9F42-1BEB7FEF8158",
    "form_completion_date": "2013-2-26",
    "pharmaceutical_therapy_drug_name": "CYCLOPHOSPHANE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 157,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 330,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "9d7305be-60a3-4ecf-856a-bd5321166590",
    "patient_ID": "TCGA.BR.6563",
    "bcr_drug_barcode": "TCGA-BR-6563-D40653",
    "bcr_drug_uuid": "84F5091F-4FCF-49AF-984B-902DEF77524F",
    "form_completion_date": "2013-2-26",
    "pharmaceutical_therapy_drug_name": "VINCRISTINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 157,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 330,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "9d7305be-60a3-4ecf-856a-bd5321166590",
    "patient_ID": "TCGA.BR.6563",
    "bcr_drug_barcode": "TCGA-BR-6563-D40655",
    "bcr_drug_uuid": "D97E90FB-801B-458A-8FB0-768EC4B13B19",
    "form_completion_date": "2013-2-26",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 157,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 330,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "93aebbd4-19cf-495a-b8ce-3c4a3feba152",
    "patient_ID": "TCGA.BR.6706",
    "bcr_drug_barcode": "TCGA-BR-6706-D31136",
    "bcr_drug_uuid": "715BDE47-0B8B-49F9-822F-674F612F117C",
    "form_completion_date": "2012-4-24",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 56,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 147,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "93aebbd4-19cf-495a-b8ce-3c4a3feba152",
    "patient_ID": "TCGA.BR.6706",
    "bcr_drug_barcode": "TCGA-BR-6706-D31137",
    "bcr_drug_uuid": "61B2F2A3-D013-4AB7-BECC-DDB957F6366E",
    "form_completion_date": "2012-4-24",
    "pharmaceutical_therapy_drug_name": "ETOPOSIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 56,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 147,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "93aebbd4-19cf-495a-b8ce-3c4a3feba152",
    "patient_ID": "TCGA.BR.6706",
    "bcr_drug_barcode": "TCGA-BR-6706-D31138",
    "bcr_drug_uuid": "2436ADA9-C071-4061-A8B1-39F90E7130FF",
    "form_completion_date": "2012-4-24",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 56,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 147,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "93aebbd4-19cf-495a-b8ce-3c4a3feba152",
    "patient_ID": "TCGA.BR.6706",
    "bcr_drug_barcode": "TCGA-BR-6706-D31139",
    "bcr_drug_uuid": "5F7FE1C5-45A8-4B9A-897F-B12225B1EED0",
    "form_completion_date": "2012-4-24",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 402,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 445,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "93aebbd4-19cf-495a-b8ce-3c4a3feba152",
    "patient_ID": "TCGA.BR.6706",
    "bcr_drug_barcode": "TCGA-BR-6706-D31141",
    "bcr_drug_uuid": "34DB3E5F-3CCC-4A18-843A-2C0E4B236991",
    "form_completion_date": "2012-4-24",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 402,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 445,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "93aebbd4-19cf-495a-b8ce-3c4a3feba152",
    "patient_ID": "TCGA.BR.6706",
    "bcr_drug_barcode": "TCGA-BR-6706-D31142",
    "bcr_drug_uuid": "89A605AD-53DF-4DE1-9078-AE6BED38A4BC",
    "form_completion_date": "2012-4-24",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 402,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 410,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "93aebbd4-19cf-495a-b8ce-3c4a3feba152",
    "patient_ID": "TCGA.BR.6706",
    "bcr_drug_barcode": "TCGA-BR-6706-D48238",
    "bcr_drug_uuid": "0D4A2166-A909-44ED-973E-B89436C81B2D",
    "form_completion_date": "2013-9-10",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 441,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 445,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "df3df249-86c2-43d4-abe1-796cd7df653f",
    "patient_ID": "TCGA.BR.6707",
    "bcr_drug_barcode": "TCGA-BR-6707-D40122",
    "bcr_drug_uuid": "6AFF62B3-4BA0-4BFD-B451-FE8172EE9B2A",
    "form_completion_date": "2013-2-13",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 426,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 491,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "df3df249-86c2-43d4-abe1-796cd7df653f",
    "patient_ID": "TCGA.BR.6707",
    "bcr_drug_barcode": "TCGA-BR-6707-D40125",
    "bcr_drug_uuid": "A76318ED-0715-445A-9342-52629BA75F3D",
    "form_completion_date": "2013-2-13",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 426,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 491,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "df3df249-86c2-43d4-abe1-796cd7df653f",
    "patient_ID": "TCGA.BR.6707",
    "bcr_drug_barcode": "TCGA-BR-6707-D40136",
    "bcr_drug_uuid": "9D139348-6DC9-4EE1-B638-75BE15D7848F",
    "form_completion_date": "2013-2-13",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 426,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 491,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6f70e9f0-580b-4199-934b-dacd29fb28a0",
    "patient_ID": "TCGA.BR.6709",
    "bcr_drug_barcode": "TCGA-BR-6709-D31221",
    "bcr_drug_uuid": "4864A635-4F6F-4C10-9485-704AC74F5A4B",
    "form_completion_date": "2012-4-25",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 206,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6f70e9f0-580b-4199-934b-dacd29fb28a0",
    "patient_ID": "TCGA.BR.6709",
    "bcr_drug_barcode": "TCGA-BR-6709-D31222",
    "bcr_drug_uuid": "F0C88A74-DF3A-4D22-AEDF-7F0E70E0680F",
    "form_completion_date": "2012-4-25",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 206,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6f70e9f0-580b-4199-934b-dacd29fb28a0",
    "patient_ID": "TCGA.BR.6709",
    "bcr_drug_barcode": "TCGA-BR-6709-D31224",
    "bcr_drug_uuid": "6C068635-DBC3-4E67-9F40-AC44B0357F25",
    "form_completion_date": "2012-4-25",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 206,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6f70e9f0-580b-4199-934b-dacd29fb28a0",
    "patient_ID": "TCGA.BR.6709",
    "bcr_drug_barcode": "TCGA-BR-6709-D40140",
    "bcr_drug_uuid": "E3F514A5-EE64-4E72-8A52-85A3A43E8AA0",
    "form_completion_date": "2013-2-13",
    "pharmaceutical_therapy_drug_name": "CARBOPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 206,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "012e99fe-e3e8-4bb0-bb74-5b0c9992187c",
    "patient_ID": "TCGA.BR.6710",
    "bcr_drug_barcode": "TCGA-BR-6710-D31240",
    "bcr_drug_uuid": "8ECA218B-1057-4600-936D-A13A13AE9967",
    "form_completion_date": "2012-4-25",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 78,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 85,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "012e99fe-e3e8-4bb0-bb74-5b0c9992187c",
    "patient_ID": "TCGA.BR.6710",
    "bcr_drug_barcode": "TCGA-BR-6710-D31241",
    "bcr_drug_uuid": "9E8C3054-20C3-473D-A67C-7DB67BC91F45",
    "form_completion_date": "2012-4-25",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 78,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 85,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "7c831a1d-3253-4af4-a0ff-7fe9ff9af1ce",
    "patient_ID": "TCGA.BR.6802",
    "bcr_drug_barcode": "TCGA-BR-6802-D55551",
    "bcr_drug_uuid": "C441D6D1-CFEC-4B73-B8F3-3F8611A92695",
    "form_completion_date": "2014-1-8",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 847,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 854,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "7c831a1d-3253-4af4-a0ff-7fe9ff9af1ce",
    "patient_ID": "TCGA.BR.6802",
    "bcr_drug_barcode": "TCGA-BR-6802-D55552",
    "bcr_drug_uuid": "87FBC3EE-A36B-487B-9AAD-EF6CF8BFA1E5",
    "form_completion_date": "2014-1-8",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 847,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 854,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "7c831a1d-3253-4af4-a0ff-7fe9ff9af1ce",
    "patient_ID": "TCGA.BR.6802",
    "bcr_drug_barcode": "TCGA-BR-6802-D55554",
    "bcr_drug_uuid": "3DC5F8EC-083B-4BDA-8B47-2CCB843ECD9C",
    "form_completion_date": "2014-1-8",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 875,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 940,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1b641270-18f8-4257-821b-d26179e08e28",
    "patient_ID": "TCGA.BR.7196",
    "bcr_drug_barcode": "TCGA-BR-7196-D34110",
    "bcr_drug_uuid": "EE4F8265-96A3-4C0E-9013-C4C96C438852",
    "form_completion_date": "2012-7-30",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 348,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 390,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1b641270-18f8-4257-821b-d26179e08e28",
    "patient_ID": "TCGA.BR.7196",
    "bcr_drug_barcode": "TCGA-BR-7196-D34111",
    "bcr_drug_uuid": "41E004B1-1A32-46B7-BB6A-4809C5F44CA4",
    "form_completion_date": "2012-7-30",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 348,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 390,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1b641270-18f8-4257-821b-d26179e08e28",
    "patient_ID": "TCGA.BR.7196",
    "bcr_drug_barcode": "TCGA-BR-7196-D34115",
    "bcr_drug_uuid": "0BC87D30-C6B5-44C8-8B67-E468F801CF6C",
    "form_completion_date": "2012-7-30",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 348,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 390,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1b641270-18f8-4257-821b-d26179e08e28",
    "patient_ID": "TCGA.BR.7196",
    "bcr_drug_barcode": "TCGA-BR-7196-D34116",
    "bcr_drug_uuid": "FF0CB97A-8CAF-48CE-9C1C-CCB9990FBDDE",
    "form_completion_date": "2012-7-30",
    "pharmaceutical_therapy_drug_name": "ETOPOSIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 83,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 149,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1b641270-18f8-4257-821b-d26179e08e28",
    "patient_ID": "TCGA.BR.7196",
    "bcr_drug_barcode": "TCGA-BR-7196-D34117",
    "bcr_drug_uuid": "11ACEF5E-24B9-4B3B-8452-8F49DD2B3BD8",
    "form_completion_date": "2012-7-30",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 83,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 149,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1b641270-18f8-4257-821b-d26179e08e28",
    "patient_ID": "TCGA.BR.7196",
    "bcr_drug_barcode": "TCGA-BR-7196-D34118",
    "bcr_drug_uuid": "809AB54A-55EF-4742-AD01-ABC4F7ABF642",
    "form_completion_date": "2012-7-30",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 83,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 149,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "bb3729fe-2fa2-47fc-afde-c14036cb84f5",
    "patient_ID": "TCGA.BR.7723",
    "bcr_drug_barcode": "TCGA-BR-7723-D35684",
    "bcr_drug_uuid": "DA50050C-6CA2-4E7B-B9D1-287A598AFDBB",
    "form_completion_date": "2012-10-5",
    "pharmaceutical_therapy_drug_name": "ETOPOSIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 559,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 564,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "bb3729fe-2fa2-47fc-afde-c14036cb84f5",
    "patient_ID": "TCGA.BR.7723",
    "bcr_drug_barcode": "TCGA-BR-7723-D35685",
    "bcr_drug_uuid": "9FB5C566-828D-41C2-935A-729E2604E0BD",
    "form_completion_date": "2012-10-5",
    "pharmaceutical_therapy_drug_name": "CARBOPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 559,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 564,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "bb3729fe-2fa2-47fc-afde-c14036cb84f5",
    "patient_ID": "TCGA.BR.7723",
    "bcr_drug_barcode": "TCGA-BR-7723-D35687",
    "bcr_drug_uuid": "B103EE4D-DE41-4C61-AD3C-414254C85244",
    "form_completion_date": "2012-10-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 559,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 564,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b16167d0-d7d7-408e-bd0e-ce429b7f828c",
    "patient_ID": "TCGA.BR.7959",
    "bcr_drug_barcode": "TCGA-BR-7959-D39862",
    "bcr_drug_uuid": "3880CA8D-5764-4491-92DF-20C3C89BA3C2",
    "form_completion_date": "2013-2-5",
    "pharmaceutical_therapy_drug_name": "ETOPOSIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 35,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 127,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "264b781d-122b-433d-80d4-59fbec262f22",
    "patient_ID": "TCGA.BR.8291",
    "bcr_drug_barcode": "TCGA-BR-8291-D41695",
    "bcr_drug_uuid": "26144004-F993-42B6-85B0-A551B6560AEE",
    "form_completion_date": "2013-3-26",
    "pharmaceutical_therapy_drug_name": "ETOPOSIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 39,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 137,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "264b781d-122b-433d-80d4-59fbec262f22",
    "patient_ID": "TCGA.BR.8291",
    "bcr_drug_barcode": "TCGA-BR-8291-D41696",
    "bcr_drug_uuid": "E26893D2-FE11-4D1C-B1D7-144430B206B1",
    "form_completion_date": "2013-3-26",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 39,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 137,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "264b781d-122b-433d-80d4-59fbec262f22",
    "patient_ID": "TCGA.BR.8291",
    "bcr_drug_barcode": "TCGA-BR-8291-D41697",
    "bcr_drug_uuid": "584B220E-2507-46F1-8637-1102A6B4FF15",
    "form_completion_date": "2013-3-26",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 39,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 137,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2688d563-b052-440b-a810-873b1cd3666d",
    "patient_ID": "TCGA.BR.8296",
    "bcr_drug_barcode": "TCGA-BR-8296-D53160",
    "bcr_drug_uuid": "883E7772-5357-421B-85DA-331D4187433B",
    "form_completion_date": "2014-1-24",
    "pharmaceutical_therapy_drug_name": "ETOPOSIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 44,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 180,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2688d563-b052-440b-a810-873b1cd3666d",
    "patient_ID": "TCGA.BR.8296",
    "bcr_drug_barcode": "TCGA-BR-8296-D53167",
    "bcr_drug_uuid": "911881EA-DF47-4C2D-9EDD-9E3CE3FCE56E",
    "form_completion_date": "2014-1-24",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 44,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 180,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2688d563-b052-440b-a810-873b1cd3666d",
    "patient_ID": "TCGA.BR.8296",
    "bcr_drug_barcode": "TCGA-BR-8296-D53166",
    "bcr_drug_uuid": "D1885FC4-DF71-4086-8FAB-F30BB5DF3D78",
    "form_completion_date": "2014-1-24",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 44,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 180,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "304aab66-4a2a-4b9f-af87-4a591d518ca1",
    "patient_ID": "TCGA.BR.8297",
    "bcr_drug_barcode": "TCGA-BR-8297-D53178",
    "bcr_drug_uuid": "5136C06C-8AAC-4409-B8E6-093BD0F0AD51",
    "form_completion_date": "2013-12-10",
    "pharmaceutical_therapy_drug_name": "ETOPOSIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 67,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 97,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "304aab66-4a2a-4b9f-af87-4a591d518ca1",
    "patient_ID": "TCGA.BR.8297",
    "bcr_drug_barcode": "TCGA-BR-8297-D53182",
    "bcr_drug_uuid": "ABB09F9E-B07E-49A4-8596-AA2B28F56838",
    "form_completion_date": "2013-12-10",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 67,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 97,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "304aab66-4a2a-4b9f-af87-4a591d518ca1",
    "patient_ID": "TCGA.BR.8297",
    "bcr_drug_barcode": "TCGA-BR-8297-D53190",
    "bcr_drug_uuid": "8CF026A8-C838-4DFC-B518-BEEBF4DF9F00",
    "form_completion_date": "2013-12-10",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 67,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 97,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "bdfd84fa-a8b9-46cd-b618-1267590da864",
    "patient_ID": "TCGA.BR.8362",
    "bcr_drug_barcode": "TCGA-BR-8362-D53221",
    "bcr_drug_uuid": "732BB094-D0C1-4990-BC97-28A86AD82C9B",
    "form_completion_date": "2013-12-10",
    "pharmaceutical_therapy_drug_name": "ETOPOSIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 24,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 154,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "bdfd84fa-a8b9-46cd-b618-1267590da864",
    "patient_ID": "TCGA.BR.8362",
    "bcr_drug_barcode": "TCGA-BR-8362-D53222",
    "bcr_drug_uuid": "399C0ADA-6AAB-4323-9D45-37FC06D62F50",
    "form_completion_date": "2013-12-10",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 24,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 154,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "bdfd84fa-a8b9-46cd-b618-1267590da864",
    "patient_ID": "TCGA.BR.8362",
    "bcr_drug_barcode": "TCGA-BR-8362-D53224",
    "bcr_drug_uuid": "81189E50-888D-4571-A824-50BA383B1C86",
    "form_completion_date": "2013-12-10",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 24,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 154,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "bdfd84fa-a8b9-46cd-b618-1267590da864",
    "patient_ID": "TCGA.BR.8362",
    "bcr_drug_barcode": "TCGA-BR-8362-D53227",
    "bcr_drug_uuid": "3D5BE428-69B9-46E5-B1E0-FF6088F64E0E",
    "form_completion_date": "2013-12-10",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 370,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 375,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "bdfd84fa-a8b9-46cd-b618-1267590da864",
    "patient_ID": "TCGA.BR.8362",
    "bcr_drug_barcode": "TCGA-BR-8362-D53229",
    "bcr_drug_uuid": "2187C5A2-169D-47DE-8241-B5C1C986C3F8",
    "form_completion_date": "2013-12-10",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 370,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 375,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "bdfd84fa-a8b9-46cd-b618-1267590da864",
    "patient_ID": "TCGA.BR.8362",
    "bcr_drug_barcode": "TCGA-BR-8362-D53230",
    "bcr_drug_uuid": "E378C034-A069-42B4-8CF9-8667B1EF2FD1",
    "form_completion_date": "2013-12-10",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 370,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 375,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b12d9857-9ae1-445b-a963-b630b27b254e",
    "patient_ID": "TCGA.BR.8367",
    "bcr_drug_barcode": "TCGA-BR-8367-D40165",
    "bcr_drug_uuid": "BC75D8B6-0D76-47BC-885B-DCFD18EE3CAF",
    "form_completion_date": "2013-2-13",
    "pharmaceutical_therapy_drug_name": "ETOPOSIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 163,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b12d9857-9ae1-445b-a963-b630b27b254e",
    "patient_ID": "TCGA.BR.8367",
    "bcr_drug_barcode": "TCGA-BR-8367-D40166",
    "bcr_drug_uuid": "3CA60D71-63FC-4034-8162-554BC4A29562",
    "form_completion_date": "2013-2-13",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 229,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b12d9857-9ae1-445b-a963-b630b27b254e",
    "patient_ID": "TCGA.BR.8367",
    "bcr_drug_barcode": "TCGA-BR-8367-D40167",
    "bcr_drug_uuid": "2708C1A4-9D1E-4119-8746-32E749EAE3FF",
    "form_completion_date": "2013-2-13",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 229,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b12d9857-9ae1-445b-a963-b630b27b254e",
    "patient_ID": "TCGA.BR.8367",
    "bcr_drug_barcode": "TCGA-BR-8367-D55901",
    "bcr_drug_uuid": "777057FE-2A44-418C-BDF7-4AC6362CFDB8",
    "form_completion_date": "2014-1-17",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 189,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 611,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b12d9857-9ae1-445b-a963-b630b27b254e",
    "patient_ID": "TCGA.BR.8367",
    "bcr_drug_barcode": "TCGA-BR-8367-D55902",
    "bcr_drug_uuid": "49A7FB08-D143-4F26-B559-7045FAB31983",
    "form_completion_date": "2014-1-17",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 189,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 611,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b12d9857-9ae1-445b-a963-b630b27b254e",
    "patient_ID": "TCGA.BR.8367",
    "bcr_drug_barcode": "TCGA-BR-8367-D55903",
    "bcr_drug_uuid": "76E85FC6-ECE8-47D0-88CE-CE9E7B33EFF4",
    "form_completion_date": "2014-1-17",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 189,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 611,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "cae32f61-6b84-4122-af33-d8cbf410d4c8",
    "patient_ID": "TCGA.BR.8370",
    "bcr_drug_barcode": "TCGA-BR-8370-D41718",
    "bcr_drug_uuid": "2B007983-2174-4949-AB60-59813177CDB2",
    "form_completion_date": "2013-3-26",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 34,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 101,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "cae32f61-6b84-4122-af33-d8cbf410d4c8",
    "patient_ID": "TCGA.BR.8370",
    "bcr_drug_barcode": "TCGA-BR-8370-D41719",
    "bcr_drug_uuid": "6D0CF2F4-7914-4814-ACFA-A2CF3C5DF667",
    "form_completion_date": "2013-3-26",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 34,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 101,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "cae32f61-6b84-4122-af33-d8cbf410d4c8",
    "patient_ID": "TCGA.BR.8370",
    "bcr_drug_barcode": "TCGA-BR-8370-D41720",
    "bcr_drug_uuid": "53DC2805-138F-4C32-9C80-E78660E5F4EC",
    "form_completion_date": "2013-3-26",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 34,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 101,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4020b1b1-576d-4869-9ff5-552e3afb3ab5",
    "patient_ID": "TCGA.BR.8371",
    "bcr_drug_barcode": "TCGA-BR-8371-D41722",
    "bcr_drug_uuid": "06207711-8147-42E4-938A-A602B8425ECD",
    "form_completion_date": "2013-3-26",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 189,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4020b1b1-576d-4869-9ff5-552e3afb3ab5",
    "patient_ID": "TCGA.BR.8371",
    "bcr_drug_barcode": "TCGA-BR-8371-D41723",
    "bcr_drug_uuid": "39523C55-7A3A-4A20-9378-88B060DD0AF6",
    "form_completion_date": "2013-3-26",
    "pharmaceutical_therapy_drug_name": "POLYPLATILLEN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 81,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 98,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4020b1b1-576d-4869-9ff5-552e3afb3ab5",
    "patient_ID": "TCGA.BR.8371",
    "bcr_drug_barcode": "TCGA-BR-8371-D41725",
    "bcr_drug_uuid": "1A29866F-A3AB-406F-ADD0-E2AA26F08165",
    "form_completion_date": "2013-3-26",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 189,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4020b1b1-576d-4869-9ff5-552e3afb3ab5",
    "patient_ID": "TCGA.BR.8371",
    "bcr_drug_barcode": "TCGA-BR-8371-D41728",
    "bcr_drug_uuid": "D3A9D9D2-E811-4F2C-8816-FCA1D0200F11",
    "form_completion_date": "2013-3-26",
    "pharmaceutical_therapy_drug_name": "POLYPLATILLEN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 337,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 351,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4020b1b1-576d-4869-9ff5-552e3afb3ab5",
    "patient_ID": "TCGA.BR.8371",
    "bcr_drug_barcode": "TCGA-BR-8371-D41731",
    "bcr_drug_uuid": "DE1CD845-D8FA-4318-AAFC-3A9053C205BC",
    "form_completion_date": "2013-3-26",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 119,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 189,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4020b1b1-576d-4869-9ff5-552e3afb3ab5",
    "patient_ID": "TCGA.BR.8371",
    "bcr_drug_barcode": "TCGA-BR-8371-D41732",
    "bcr_drug_uuid": "49322124-6697-43E0-8BBB-424DA948A388",
    "form_completion_date": "2013-3-26",
    "pharmaceutical_therapy_drug_name": "ETOPOSIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 337,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 351,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5b52f882-df12-42ec-a000-ff3b428ba05b",
    "patient_ID": "TCGA.BR.8372",
    "bcr_drug_barcode": "TCGA-BR-8372-D53201",
    "bcr_drug_uuid": "4DB82487-E263-4102-99E7-7EC2DAB13F5B",
    "form_completion_date": "2013-12-10",
    "pharmaceutical_therapy_drug_name": "ETOPOSIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 174,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5b52f882-df12-42ec-a000-ff3b428ba05b",
    "patient_ID": "TCGA.BR.8372",
    "bcr_drug_barcode": "TCGA-BR-8372-D53202",
    "bcr_drug_uuid": "B686B5C4-1EBD-4647-8AA4-CE4A544BEABF",
    "form_completion_date": "2013-12-10",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 174,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5b52f882-df12-42ec-a000-ff3b428ba05b",
    "patient_ID": "TCGA.BR.8372",
    "bcr_drug_barcode": "TCGA-BR-8372-D53204",
    "bcr_drug_uuid": "6D0352BA-28AF-4EBC-863E-FC948E4F7720",
    "form_completion_date": "2013-12-10",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 174,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "60879669-96c2-4710-82e0-0ae9d0e5b242",
    "patient_ID": "TCGA.BR.8373",
    "bcr_drug_barcode": "TCGA-BR-8373-D40169",
    "bcr_drug_uuid": "78B475A5-C995-4AD6-BDFD-19A87889ED5D",
    "form_completion_date": "2013-2-13",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 55,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 84,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "60879669-96c2-4710-82e0-0ae9d0e5b242",
    "patient_ID": "TCGA.BR.8373",
    "bcr_drug_barcode": "TCGA-BR-8373-D40170",
    "bcr_drug_uuid": "D853330E-86D9-43F4-B5C8-E54132D3399B",
    "form_completion_date": "2013-2-13",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 55,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 84,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "60879669-96c2-4710-82e0-0ae9d0e5b242",
    "patient_ID": "TCGA.BR.8373",
    "bcr_drug_barcode": "TCGA-BR-8373-D57688",
    "bcr_drug_uuid": "360A35DC-AE12-4DB1-A11B-FC5DB2F0F704",
    "form_completion_date": "2014-3-19",
    "pharmaceutical_therapy_drug_name": "ETOPOSIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 55,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 84,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "9ebc8b58-363b-4638-8365-cfbde31a71ae",
    "patient_ID": "TCGA.BR.8380",
    "bcr_drug_barcode": "TCGA-BR-8380-D64092",
    "bcr_drug_uuid": "523D5ED3-96F6-4CA5-8A77-ED8DAA5ADFB8",
    "form_completion_date": "2014-8-26",
    "pharmaceutical_therapy_drug_name": "POLYPLATILLEN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 69,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 190,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "9ebc8b58-363b-4638-8365-cfbde31a71ae",
    "patient_ID": "TCGA.BR.8380",
    "bcr_drug_barcode": "TCGA-BR-8380-D65474",
    "bcr_drug_uuid": "1D379E6A-1888-4119-B693-F50005318DC2",
    "form_completion_date": "2014-12-15",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 69,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 190,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "9ebc8b58-363b-4638-8365-cfbde31a71ae",
    "patient_ID": "TCGA.BR.8380",
    "bcr_drug_barcode": "TCGA-BR-8380-D65476",
    "bcr_drug_uuid": "227B492A-CBAA-45B6-A90B-13A7402F2EFB",
    "form_completion_date": "2014-12-15",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 69,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 190,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "aef8d98f-7a1c-47f3-b5a7-a3cb299c70de",
    "patient_ID": "TCGA.BR.8381",
    "bcr_drug_barcode": "TCGA-BR-8381-D42015",
    "bcr_drug_uuid": "C2B0E7FB-E1DA-4B20-B143-57B2638F3BBA",
    "form_completion_date": "2013-4-9",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 35,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 161,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "aef8d98f-7a1c-47f3-b5a7-a3cb299c70de",
    "patient_ID": "TCGA.BR.8381",
    "bcr_drug_barcode": "TCGA-BR-8381-D42017",
    "bcr_drug_uuid": "8C009156-7F0B-4F2F-8E69-9A9DFE7D3658",
    "form_completion_date": "2013-4-9",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 35,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 161,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "aef8d98f-7a1c-47f3-b5a7-a3cb299c70de",
    "patient_ID": "TCGA.BR.8381",
    "bcr_drug_barcode": "TCGA-BR-8381-D42018",
    "bcr_drug_uuid": "08EFC579-4985-430F-9871-ADC8A1A9E6A1",
    "form_completion_date": "2013-4-9",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 35,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 161,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "e17cf9e9-0902-44e0-962b-af5492876f7d",
    "patient_ID": "TCGA.BR.8483",
    "bcr_drug_barcode": "TCGA-BR-8483-D49892",
    "bcr_drug_uuid": "972704B6-DC8C-4BAC-A026-F1C378A84E8F",
    "form_completion_date": "2014-1-24",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 63,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 161,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "e17cf9e9-0902-44e0-962b-af5492876f7d",
    "patient_ID": "TCGA.BR.8483",
    "bcr_drug_barcode": "TCGA-BR-8483-D49893",
    "bcr_drug_uuid": "160E024D-8EDA-44DB-8338-C71FD24E62AC",
    "form_completion_date": "2014-1-24",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 63,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 161,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "d59824bd-816e-4ffc-8aae-1c3eff1f800e",
    "patient_ID": "TCGA.BR.8590",
    "bcr_drug_barcode": "TCGA-BR-8590-D53253",
    "bcr_drug_uuid": "325CB6D7-65E1-40C6-B0B4-63B9CB24A935",
    "form_completion_date": "2013-12-10",
    "pharmaceutical_therapy_drug_name": "ETOPOSIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 42,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 203,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "d59824bd-816e-4ffc-8aae-1c3eff1f800e",
    "patient_ID": "TCGA.BR.8590",
    "bcr_drug_barcode": "TCGA-BR-8590-D53256",
    "bcr_drug_uuid": "2C4B31CD-54A0-4540-9FCB-F6AAE16381EC",
    "form_completion_date": "2013-12-10",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 42,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 203,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "d59824bd-816e-4ffc-8aae-1c3eff1f800e",
    "patient_ID": "TCGA.BR.8590",
    "bcr_drug_barcode": "TCGA-BR-8590-D53257",
    "bcr_drug_uuid": "6327A80C-7AE5-4A40-BE50-D547E2A2AD38",
    "form_completion_date": "2013-12-10",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 42,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 203,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "a4cd4ff1-0c0e-488d-91d9-0ac8ef3e7bfd",
    "patient_ID": "TCGA.BR.8592",
    "bcr_drug_barcode": "TCGA-BR-8592-D53276",
    "bcr_drug_uuid": "C914FED2-B0DD-4957-A07E-DB167239AE8F",
    "form_completion_date": "2014-1-27",
    "pharmaceutical_therapy_drug_name": "ETOPOSIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 39,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 113,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "a4cd4ff1-0c0e-488d-91d9-0ac8ef3e7bfd",
    "patient_ID": "TCGA.BR.8592",
    "bcr_drug_barcode": "TCGA-BR-8592-D53277",
    "bcr_drug_uuid": "06B7264E-34CB-4CC7-AB90-8F9174C237EC",
    "form_completion_date": "2014-1-27",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 39,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 113,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "a4cd4ff1-0c0e-488d-91d9-0ac8ef3e7bfd",
    "patient_ID": "TCGA.BR.8592",
    "bcr_drug_barcode": "TCGA-BR-8592-D53278",
    "bcr_drug_uuid": "7782D6BF-9D71-43B9-9501-593A884F94DE",
    "form_completion_date": "2014-1-27",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 39,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 113,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "ab76544e-df6a-4b05-9317-054812474d4c",
    "patient_ID": "TCGA.BR.8680",
    "bcr_drug_barcode": "TCGA-BR-8680-D48354",
    "bcr_drug_uuid": "85D9F46B-ED79-4A17-A571-6FFFE1ACEDEF",
    "form_completion_date": "2013-9-12",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 39,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 150,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "ab76544e-df6a-4b05-9317-054812474d4c",
    "patient_ID": "TCGA.BR.8680",
    "bcr_drug_barcode": "TCGA-BR-8680-D48356",
    "bcr_drug_uuid": "9C291267-1086-4C46-8246-A311629B13F3",
    "form_completion_date": "2013-9-12",
    "pharmaceutical_therapy_drug_name": "HALAVEN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 39,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 150,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "ab76544e-df6a-4b05-9317-054812474d4c",
    "patient_ID": "TCGA.BR.8680",
    "bcr_drug_barcode": "TCGA-BR-8680-D48357",
    "bcr_drug_uuid": "77B95195-E8D9-4E5D-964E-6972CB801422",
    "form_completion_date": "2013-9-12",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 39,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 150,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "ab76544e-df6a-4b05-9317-054812474d4c",
    "patient_ID": "TCGA.BR.8680",
    "bcr_drug_barcode": "TCGA-BR-8680-D48358",
    "bcr_drug_uuid": "50EF1ACB-4270-425D-A523-E55A8E9FEF9E",
    "form_completion_date": "2013-9-12",
    "pharmaceutical_therapy_drug_name": "MEDROL",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 39,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 150,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "d5efcde2-21e6-4071-9aa4-3c5688a45b3f",
    "patient_ID": "TCGA.BR.8682",
    "bcr_drug_barcode": "TCGA-BR-8682-D48360",
    "bcr_drug_uuid": "6FEB3C22-7D84-4166-805D-5A5A3C66903D",
    "form_completion_date": "2013-10-7",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 60,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 181,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "d5efcde2-21e6-4071-9aa4-3c5688a45b3f",
    "patient_ID": "TCGA.BR.8682",
    "bcr_drug_barcode": "TCGA-BR-8682-D48361",
    "bcr_drug_uuid": "4A3F18D6-CDB8-4611-B6FC-AE541A9402B6",
    "form_completion_date": "2013-10-7",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 60,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 181,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "d5efcde2-21e6-4071-9aa4-3c5688a45b3f",
    "patient_ID": "TCGA.BR.8682",
    "bcr_drug_barcode": "TCGA-BR-8682-D48362",
    "bcr_drug_uuid": "384CDBA6-34F9-4A2A-92CE-93A1C2C071D8",
    "form_completion_date": "2013-10-7",
    "pharmaceutical_therapy_drug_name": "DEXAMETHASONE",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 60,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 181,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "d5efcde2-21e6-4071-9aa4-3c5688a45b3f",
    "patient_ID": "TCGA.BR.8682",
    "bcr_drug_barcode": "TCGA-BR-8682-D48363",
    "bcr_drug_uuid": "DE872954-0DAF-4036-84E2-E18B9DA3C859",
    "form_completion_date": "2013-10-7",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 60,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 181,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "337819d2-5281-4b41-9583-a476924bc837",
    "patient_ID": "TCGA.BR.8690",
    "bcr_drug_barcode": "TCGA-BR-8690-D48712",
    "bcr_drug_uuid": "7FF54FB1-80DD-4E70-B211-7EBC8955C5C9",
    "form_completion_date": "2013-9-19",
    "pharmaceutical_therapy_drug_name": "CARBOPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 58,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 196,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "337819d2-5281-4b41-9583-a476924bc837",
    "patient_ID": "TCGA.BR.8690",
    "bcr_drug_barcode": "TCGA-BR-8690-D48713",
    "bcr_drug_uuid": "74EE5D8C-B363-406C-A99B-953F95273FC2",
    "form_completion_date": "2013-9-19",
    "pharmaceutical_therapy_drug_name": "ETOPOSIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 118,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 122,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "337819d2-5281-4b41-9583-a476924bc837",
    "patient_ID": "TCGA.BR.8690",
    "bcr_drug_barcode": "TCGA-BR-8690-D48714",
    "bcr_drug_uuid": "C0D1267D-9626-45F5-B66D-CB6580F1A8F5",
    "form_completion_date": "2013-9-19",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 58,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 122,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "337819d2-5281-4b41-9583-a476924bc837",
    "patient_ID": "TCGA.BR.8690",
    "bcr_drug_barcode": "TCGA-BR-8690-D48720",
    "bcr_drug_uuid": "65D1D06D-D48A-4C86-B6C2-D1AAB0F0F5CB",
    "form_completion_date": "2013-9-19",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 118,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 122,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "98BF4652-0088-4ECC-9DFA-376438CB063C",
    "patient_ID": "TCGA.BR.A44T",
    "bcr_drug_barcode": "TCGA-BR-A44T-D46406",
    "bcr_drug_uuid": "C1431FDD-005A-465F-8795-AA4F2ACFDABD",
    "form_completion_date": "2013-8-7",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 47,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 196,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "98BF4652-0088-4ECC-9DFA-376438CB063C",
    "patient_ID": "TCGA.BR.A44T",
    "bcr_drug_barcode": "TCGA-BR-A44T-D46407",
    "bcr_drug_uuid": "6DD0DFAA-BDF7-49DE-B36D-97C3DE91998A",
    "form_completion_date": "2013-8-7",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 47,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 196,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "98BF4652-0088-4ECC-9DFA-376438CB063C",
    "patient_ID": "TCGA.BR.A44T",
    "bcr_drug_barcode": "TCGA-BR-A44T-D60631",
    "bcr_drug_uuid": "54B88AB0-93C0-4219-BCAC-E560497ACF94",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 682,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 714,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "98BF4652-0088-4ECC-9DFA-376438CB063C",
    "patient_ID": "TCGA.BR.A44T",
    "bcr_drug_barcode": "TCGA-BR-A44T-D60632",
    "bcr_drug_uuid": "1764350C-63FD-4DFD-B592-6465C29A1419",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 682,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 714,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "98BF4652-0088-4ECC-9DFA-376438CB063C",
    "patient_ID": "TCGA.BR.A44T",
    "bcr_drug_barcode": "TCGA-BR-A44T-D60633",
    "bcr_drug_uuid": "CFD30708-A79C-41AA-9A12-82E2FEF8411B",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "ETOPOSIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 682,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 714,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AF59B21E-2805-4C0B-8AAD-C99B26C79EE1",
    "patient_ID": "TCGA.BR.A4IU",
    "bcr_drug_barcode": "TCGA-BR-A4IU-D48368",
    "bcr_drug_uuid": "5DAEB4B4-652A-4DD6-BA78-9A0DFCAF848E",
    "form_completion_date": "2013-9-12",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 47,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 156,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AF59B21E-2805-4C0B-8AAD-C99B26C79EE1",
    "patient_ID": "TCGA.BR.A4IU",
    "bcr_drug_barcode": "TCGA-BR-A4IU-D48369",
    "bcr_drug_uuid": "2CB12066-9402-4FCB-BA2B-C2A739F3178C",
    "form_completion_date": "2013-9-12",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 47,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 156,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AF59B21E-2805-4C0B-8AAD-C99B26C79EE1",
    "patient_ID": "TCGA.BR.A4IU",
    "bcr_drug_barcode": "TCGA-BR-A4IU-D48370",
    "bcr_drug_uuid": "9FD32065-1967-44E0-844B-17E05071FE4D",
    "form_completion_date": "2013-9-12",
    "pharmaceutical_therapy_drug_name": "DEXAMETHASONE",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 47,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 156,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "30425882-20D7-47ED-9630-60977BA62C72",
    "patient_ID": "TCGA.BR.A4IV",
    "bcr_drug_barcode": "TCGA-BR-A4IV-D48374",
    "bcr_drug_uuid": "9607C0FC-B41D-4206-AF5A-1D07B21ED651",
    "form_completion_date": "2013-9-12",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 51,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 166,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "30425882-20D7-47ED-9630-60977BA62C72",
    "patient_ID": "TCGA.BR.A4IV",
    "bcr_drug_barcode": "TCGA-BR-A4IV-D48375",
    "bcr_drug_uuid": "088714CC-ACF2-45A6-9333-D17F30500A7D",
    "form_completion_date": "2013-9-12",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 51,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 166,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "30425882-20D7-47ED-9630-60977BA62C72",
    "patient_ID": "TCGA.BR.A4IV",
    "bcr_drug_barcode": "TCGA-BR-A4IV-D48376",
    "bcr_drug_uuid": "44223653-15E7-4147-A96F-D94FC6087DD3",
    "form_completion_date": "2013-9-12",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 51,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 166,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "30425882-20D7-47ED-9630-60977BA62C72",
    "patient_ID": "TCGA.BR.A4IV",
    "bcr_drug_barcode": "TCGA-BR-A4IV-D48379",
    "bcr_drug_uuid": "B93DFA57-F320-4EAB-A63C-729C88CF3EFD",
    "form_completion_date": "2013-9-12",
    "pharmaceutical_therapy_drug_name": "DEXAMETHASONE",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 51,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 166,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "98C56F92-547B-473D-9FE0-2135DD5A96A8",
    "patient_ID": "TCGA.BR.A4IY",
    "bcr_drug_barcode": "TCGA-BR-A4IY-D48380",
    "bcr_drug_uuid": "E88DF1F0-B216-4AB7-BFFE-F01D9777ECF0",
    "form_completion_date": "2013-9-12",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 47,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 177,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "98C56F92-547B-473D-9FE0-2135DD5A96A8",
    "patient_ID": "TCGA.BR.A4IY",
    "bcr_drug_barcode": "TCGA-BR-A4IY-D48381",
    "bcr_drug_uuid": "0CE8FB91-8C39-4B33-92EA-63F8711B7651",
    "form_completion_date": "2013-9-12",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 47,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 177,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "98C56F92-547B-473D-9FE0-2135DD5A96A8",
    "patient_ID": "TCGA.BR.A4IY",
    "bcr_drug_barcode": "TCGA-BR-A4IY-D48382",
    "bcr_drug_uuid": "87E368CF-2B82-4C16-88DA-AA73CBF97A74",
    "form_completion_date": "2013-9-12",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 47,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 177,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "98C56F92-547B-473D-9FE0-2135DD5A96A8",
    "patient_ID": "TCGA.BR.A4IY",
    "bcr_drug_barcode": "TCGA-BR-A4IY-D48383",
    "bcr_drug_uuid": "311865C2-C577-46CF-AC6B-981D398F1C6A",
    "form_completion_date": "2013-9-12",
    "pharmaceutical_therapy_drug_name": "DEXAMETHASONE",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 47,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 177,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "12F63577-7FAE-4FC8-9106-39729669FDFE",
    "patient_ID": "TCGA.BR.A4J2",
    "bcr_drug_barcode": "TCGA-BR-A4J2-D49238",
    "bcr_drug_uuid": "EAEBE00E-E594-4195-8B15-1067464DF4D5",
    "form_completion_date": "2013-9-27",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 51,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 125,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "12F63577-7FAE-4FC8-9106-39729669FDFE",
    "patient_ID": "TCGA.BR.A4J2",
    "bcr_drug_barcode": "TCGA-BR-A4J2-D49239",
    "bcr_drug_uuid": "AA7CD2AC-63EB-47E4-8D92-95889DFCDEA1",
    "form_completion_date": "2013-9-27",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 51,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 125,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "12F63577-7FAE-4FC8-9106-39729669FDFE",
    "patient_ID": "TCGA.BR.A4J2",
    "bcr_drug_barcode": "TCGA-BR-A4J2-D49241",
    "bcr_drug_uuid": "CB3C98C3-DA33-46D7-B123-084170F6FC77",
    "form_completion_date": "2013-9-27",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 51,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 125,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "12F63577-7FAE-4FC8-9106-39729669FDFE",
    "patient_ID": "TCGA.BR.A4J2",
    "bcr_drug_barcode": "TCGA-BR-A4J2-D49242",
    "bcr_drug_uuid": "7A15B382-6A69-4EDC-8843-BDD9BB1E821A",
    "form_completion_date": "2013-9-27",
    "pharmaceutical_therapy_drug_name": "DEXAMETHASONE",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 51,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 125,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "12F63577-7FAE-4FC8-9106-39729669FDFE",
    "patient_ID": "TCGA.BR.A4J2",
    "bcr_drug_barcode": "TCGA-BR-A4J2-D49245",
    "bcr_drug_uuid": "C7E39B7B-030B-4FD1-BC4E-9626D8E57C68",
    "form_completion_date": "2013-9-27",
    "pharmaceutical_therapy_drug_name": "LEUKINE",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 51,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 125,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1EB2038D-3B4F-4DA2-964B-E629EA068215",
    "patient_ID": "TCGA.BR.A4J8",
    "bcr_drug_barcode": "TCGA-BR-A4J8-D51399",
    "bcr_drug_uuid": "250C42A3-9507-42DD-B09A-16E3FAAC1A9E",
    "form_completion_date": "2013-11-18",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 65,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 77,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8BB9CFD8-7012-41B1-8AA1-B6592B0C0D43",
    "patient_ID": "TCGA.BR.A4QI",
    "bcr_drug_barcode": "TCGA-BR-A4QI-D51448",
    "bcr_drug_uuid": "95742FF3-4373-4FA6-9238-8EA5710150E0",
    "form_completion_date": "2013-11-19",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 383,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8BB9CFD8-7012-41B1-8AA1-B6592B0C0D43",
    "patient_ID": "TCGA.BR.A4QI",
    "bcr_drug_barcode": "TCGA-BR-A4QI-D51449",
    "bcr_drug_uuid": "E985089E-25FA-4999-9225-9DF5C938C444",
    "form_completion_date": "2013-11-19",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 383,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8BB9CFD8-7012-41B1-8AA1-B6592B0C0D43",
    "patient_ID": "TCGA.BR.A4QI",
    "bcr_drug_barcode": "TCGA-BR-A4QI-D51450",
    "bcr_drug_uuid": "144A0394-2BB9-41DF-90C6-AC3197DBAFC9",
    "form_completion_date": "2013-11-19",
    "pharmaceutical_therapy_drug_name": "ETOPOSIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 383,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8BB9CFD8-7012-41B1-8AA1-B6592B0C0D43",
    "patient_ID": "TCGA.BR.A4QI",
    "bcr_drug_barcode": "TCGA-BR-A4QI-D66455",
    "bcr_drug_uuid": "899F037D-B548-4CB9-B8F2-27231B13F601",
    "form_completion_date": "2014-10-15",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 383,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 551,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8BB9CFD8-7012-41B1-8AA1-B6592B0C0D43",
    "patient_ID": "TCGA.BR.A4QI",
    "bcr_drug_barcode": "TCGA-BR-A4QI-D66456",
    "bcr_drug_uuid": "D5539FD8-CD62-4E80-B376-1B7C3A341BF7",
    "form_completion_date": "2014-10-15",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 383,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 551,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8BB9CFD8-7012-41B1-8AA1-B6592B0C0D43",
    "patient_ID": "TCGA.BR.A4QI",
    "bcr_drug_barcode": "TCGA-BR-A4QI-D66457",
    "bcr_drug_uuid": "9F1F2449-F67D-48B0-B24E-02408C00666A",
    "form_completion_date": "2014-10-15",
    "pharmaceutical_therapy_drug_name": "ETOPOSIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 383,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 551,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AA2C5D29-2764-4804-9181-5870C0956904",
    "patient_ID": "TCGA.BR.A4QL",
    "bcr_drug_barcode": "TCGA-BR-A4QL-D51452",
    "bcr_drug_uuid": "C8A99731-355D-40FE-BE66-8A3934502D5D",
    "form_completion_date": "2013-11-19",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 59,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 90,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AA2C5D29-2764-4804-9181-5870C0956904",
    "patient_ID": "TCGA.BR.A4QL",
    "bcr_drug_barcode": "TCGA-BR-A4QL-D51453",
    "bcr_drug_uuid": "DE301F9E-1B4A-4324-BA8A-0ECA616E025D",
    "form_completion_date": "2013-11-19",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 59,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 90,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AA2C5D29-2764-4804-9181-5870C0956904",
    "patient_ID": "TCGA.BR.A4QL",
    "bcr_drug_barcode": "TCGA-BR-A4QL-D51454",
    "bcr_drug_uuid": "7C73C91F-0AC8-4C52-AAF5-87165029234B",
    "form_completion_date": "2013-11-19",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 59,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 90,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AA2C5D29-2764-4804-9181-5870C0956904",
    "patient_ID": "TCGA.BR.A4QL",
    "bcr_drug_barcode": "TCGA-BR-A4QL-D51455",
    "bcr_drug_uuid": "5B4FE56D-41B5-481E-B382-E7B0D479EC6C",
    "form_completion_date": "2013-11-19",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 48,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AA2C5D29-2764-4804-9181-5870C0956904",
    "patient_ID": "TCGA.BR.A4QL",
    "bcr_drug_barcode": "TCGA-BR-A4QL-D51456",
    "bcr_drug_uuid": "771861FC-3CAA-44CA-8B64-CE00FA2F6962",
    "form_completion_date": "2013-11-19",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 48,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0E99C305-C69F-4FB4-84D6-29CAC1CC9D39",
    "patient_ID": "TCGA.BR.A4QM",
    "bcr_drug_barcode": "TCGA-BR-A4QM-D51459",
    "bcr_drug_uuid": "C8119E42-7DA9-4387-9F23-D406593E1B46",
    "form_completion_date": "2013-11-19",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 42,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 106,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0E99C305-C69F-4FB4-84D6-29CAC1CC9D39",
    "patient_ID": "TCGA.BR.A4QM",
    "bcr_drug_barcode": "TCGA-BR-A4QM-D51461",
    "bcr_drug_uuid": "CF7E4BDE-561E-4C8D-8186-AE4FF8041F5F",
    "form_completion_date": "2013-11-19",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 42,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 106,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0E99C305-C69F-4FB4-84D6-29CAC1CC9D39",
    "patient_ID": "TCGA.BR.A4QM",
    "bcr_drug_barcode": "TCGA-BR-A4QM-D51462",
    "bcr_drug_uuid": "A5C5001D-85FE-44E1-A2E9-7411B147D1B5",
    "form_completion_date": "2013-11-19",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 42,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 106,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0aecac64-5982-4d76-8f31-958f6a00951d",
    "patient_ID": "TCGA.CD.5802",
    "bcr_drug_barcode": "TCGA-CD-5802-D71012",
    "bcr_drug_uuid": "8C28E613-9630-474D-8414-CAA50E0F473E",
    "form_completion_date": "2015-3-12",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 123,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 217,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0aecac64-5982-4d76-8f31-958f6a00951d",
    "patient_ID": "TCGA.CD.5802",
    "bcr_drug_barcode": "TCGA-CD-5802-D71013",
    "bcr_drug_uuid": "FD070DE3-6A25-4733-BAF5-E0D9DB5874B8",
    "form_completion_date": "2015-3-12",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 123,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 217,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0aecac64-5982-4d76-8f31-958f6a00951d",
    "patient_ID": "TCGA.CD.5802",
    "bcr_drug_barcode": "TCGA-CD-5802-D71014",
    "bcr_drug_uuid": "44EE0CF3-EBD9-431B-82A9-D1E0F9C19ED9",
    "form_completion_date": "2015-3-12",
    "pharmaceutical_therapy_drug_name": "5-FLOUROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 123,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 217,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "9fa752b7-9873-4bad-9eba-8cc113705fed",
    "patient_ID": "TCGA.CD.5804",
    "bcr_drug_barcode": "TCGA-CD-5804-D70986",
    "bcr_drug_uuid": "14CBDF92-8813-4D2B-9CE7-A1EF141AA798",
    "form_completion_date": "2015-3-11",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 41,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 126,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "9fa752b7-9873-4bad-9eba-8cc113705fed",
    "patient_ID": "TCGA.CD.5804",
    "bcr_drug_barcode": "TCGA-CD-5804-D70987",
    "bcr_drug_uuid": "06F96C25-20D4-46F4-B6A3-AAC61462AC31",
    "form_completion_date": "2015-3-11",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 41,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 126,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "9fa752b7-9873-4bad-9eba-8cc113705fed",
    "patient_ID": "TCGA.CD.5804",
    "bcr_drug_barcode": "TCGA-CD-5804-D70988",
    "bcr_drug_uuid": "E0C91FBE-70FD-4AF7-A779-9FEE454E4E69",
    "form_completion_date": "2015-3-11",
    "pharmaceutical_therapy_drug_name": "CAPECITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 41,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 126,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "315b8de8-9842-4738-b23b-1d61722f9583",
    "patient_ID": "TCGA.CD.8524",
    "bcr_drug_barcode": "TCGA-CD-8524-D71009",
    "bcr_drug_uuid": "0A7EC882-C204-46DA-89E6-EA358F353380",
    "form_completion_date": "2015-3-12",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 64,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 168,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "315b8de8-9842-4738-b23b-1d61722f9583",
    "patient_ID": "TCGA.CD.8524",
    "bcr_drug_barcode": "TCGA-CD-8524-D71010",
    "bcr_drug_uuid": "5764278D-F684-4502-873B-CF0C8D57BC2F",
    "form_completion_date": "2015-3-12",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 64,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 168,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "315b8de8-9842-4738-b23b-1d61722f9583",
    "patient_ID": "TCGA.CD.8524",
    "bcr_drug_barcode": "TCGA-CD-8524-D71011",
    "bcr_drug_uuid": "57ACFF4D-102E-471A-AB34-EB004A213E71",
    "form_completion_date": "2015-3-12",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 64,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 168,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "39acb803-f282-422e-ac56-a3a50693d203",
    "patient_ID": "TCGA.CD.8525",
    "bcr_drug_barcode": "TCGA-CD-8525-D71006",
    "bcr_drug_uuid": "E5715F42-8754-439D-9142-074B419DE385",
    "form_completion_date": "2015-3-12",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 62,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 157,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "39acb803-f282-422e-ac56-a3a50693d203",
    "patient_ID": "TCGA.CD.8525",
    "bcr_drug_barcode": "TCGA-CD-8525-D71007",
    "bcr_drug_uuid": "CDD0A3A9-C58B-4FDE-BF5E-D50EBADB36AB",
    "form_completion_date": "2015-3-12",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 62,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 157,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "39acb803-f282-422e-ac56-a3a50693d203",
    "patient_ID": "TCGA.CD.8525",
    "bcr_drug_barcode": "TCGA-CD-8525-D71008",
    "bcr_drug_uuid": "7D043D0F-40AA-4288-B5BA-8567F9A04045",
    "form_completion_date": "2015-3-12",
    "pharmaceutical_therapy_drug_name": "5-FLOUROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 62,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 157,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6a9b3d65-ae15-4e3c-84ed-468e2196372b",
    "patient_ID": "TCGA.CD.8526",
    "bcr_drug_barcode": "TCGA-CD-8526-D70974",
    "bcr_drug_uuid": "E8635ECC-0E31-419C-A35F-159E87193100",
    "form_completion_date": "2015-3-11",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 62,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 111,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6a9b3d65-ae15-4e3c-84ed-468e2196372b",
    "patient_ID": "TCGA.CD.8526",
    "bcr_drug_barcode": "TCGA-CD-8526-D70975",
    "bcr_drug_uuid": "BB040B53-AA70-4E65-9F82-1E8FEB3EC19C",
    "form_completion_date": "2015-3-11",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 62,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 111,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6a9b3d65-ae15-4e3c-84ed-468e2196372b",
    "patient_ID": "TCGA.CD.8526",
    "bcr_drug_barcode": "TCGA-CD-8526-D70976",
    "bcr_drug_uuid": "43190BA9-4F9B-4061-ACBB-33C79D30D8DF",
    "form_completion_date": "2015-3-11",
    "pharmaceutical_therapy_drug_name": "CAPECITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 62,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 111,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1b98b2da-c5bf-422f-bb73-1190841fbec4",
    "patient_ID": "TCGA.CD.8527",
    "bcr_drug_barcode": "TCGA-CD-8527-D70970",
    "bcr_drug_uuid": "D1EC9F9F-DA05-4C23-9F29-CF23F24E2BA5",
    "form_completion_date": "2015-3-11",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 34,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 60,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1b98b2da-c5bf-422f-bb73-1190841fbec4",
    "patient_ID": "TCGA.CD.8527",
    "bcr_drug_barcode": "TCGA-CD-8527-D70971",
    "bcr_drug_uuid": "021DEDAC-5385-4644-935D-112C0C381E33",
    "form_completion_date": "2015-3-11",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 34,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 60,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1b98b2da-c5bf-422f-bb73-1190841fbec4",
    "patient_ID": "TCGA.CD.8527",
    "bcr_drug_barcode": "TCGA-CD-8527-D70972",
    "bcr_drug_uuid": "B1D55FC2-A4E7-4619-BABD-0859F68D7C4D",
    "form_completion_date": "2015-3-11",
    "pharmaceutical_therapy_drug_name": "CAPECITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 34,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 60,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1a1f2197-e303-46e4-8871-53f2eb2e599a",
    "patient_ID": "TCGA.CD.8528",
    "bcr_drug_barcode": "TCGA-CD-8528-D71003",
    "bcr_drug_uuid": "DE755720-EF36-4B5A-9B82-AD5417F85B40",
    "form_completion_date": "2015-3-12",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 105,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 232,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1a1f2197-e303-46e4-8871-53f2eb2e599a",
    "patient_ID": "TCGA.CD.8528",
    "bcr_drug_barcode": "TCGA-CD-8528-D71004",
    "bcr_drug_uuid": "8314ED6C-B20C-46BC-8769-A51E3BF125AA",
    "form_completion_date": "2015-3-12",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 105,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 232,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1a1f2197-e303-46e4-8871-53f2eb2e599a",
    "patient_ID": "TCGA.CD.8528",
    "bcr_drug_barcode": "TCGA-CD-8528-D71005",
    "bcr_drug_uuid": "82FA7470-7B62-4BD9-B780-6E403C8DA7A9",
    "form_completion_date": "2015-3-12",
    "pharmaceutical_therapy_drug_name": "5-FLOUROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 105,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 231,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5b7e557a-6aee-4077-b3cd-c96179e643ae",
    "patient_ID": "TCGA.CD.8529",
    "bcr_drug_barcode": "TCGA-CD-8529-D70966",
    "bcr_drug_uuid": "EF88DBFE-A5E1-452A-BB65-E714F54718C2",
    "form_completion_date": "2015-3-11",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 50,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 148,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5b7e557a-6aee-4077-b3cd-c96179e643ae",
    "patient_ID": "TCGA.CD.8529",
    "bcr_drug_barcode": "TCGA-CD-8529-D70967",
    "bcr_drug_uuid": "6FEA86DF-2F54-4214-87B5-744CDB6A0AD5",
    "form_completion_date": "2015-3-11",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 50,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 148,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5b7e557a-6aee-4077-b3cd-c96179e643ae",
    "patient_ID": "TCGA.CD.8529",
    "bcr_drug_barcode": "TCGA-CD-8529-D70968",
    "bcr_drug_uuid": "4A2225B5-1A24-4928-A360-B76086B98ACA",
    "form_completion_date": "2015-3-11",
    "pharmaceutical_therapy_drug_name": "CAPECITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 50,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 148,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0a11e958-7ec0-493c-bd7a-eb17536facd7",
    "patient_ID": "TCGA.CD.8530",
    "bcr_drug_barcode": "TCGA-CD-8530-D71000",
    "bcr_drug_uuid": "F8A66EE1-A2A5-452A-BD47-9BB4430A3245",
    "form_completion_date": "2015-3-12",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 75,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 176,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0a11e958-7ec0-493c-bd7a-eb17536facd7",
    "patient_ID": "TCGA.CD.8530",
    "bcr_drug_barcode": "TCGA-CD-8530-D71001",
    "bcr_drug_uuid": "21AF61CF-F2CF-4457-B8F7-399CAA2FE0E3",
    "form_completion_date": "2015-3-12",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 75,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 176,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0a11e958-7ec0-493c-bd7a-eb17536facd7",
    "patient_ID": "TCGA.CD.8530",
    "bcr_drug_barcode": "TCGA-CD-8530-D71002",
    "bcr_drug_uuid": "54C5A1E1-F645-4E8C-99BA-B27AE6D97178",
    "form_completion_date": "2015-3-12",
    "pharmaceutical_therapy_drug_name": "5-FLOUROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 75,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 176,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "efe8b105-b170-4679-8b97-c1142fefe069",
    "patient_ID": "TCGA.CD.8531",
    "bcr_drug_barcode": "TCGA-CD-8531-D70963",
    "bcr_drug_uuid": "65A270A1-296A-427E-8B4F-73FEA1AAC0E5",
    "form_completion_date": "2015-3-12",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 106,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 197,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "efe8b105-b170-4679-8b97-c1142fefe069",
    "patient_ID": "TCGA.CD.8531",
    "bcr_drug_barcode": "TCGA-CD-8531-D70998",
    "bcr_drug_uuid": "E8A3276E-BA68-4AC1-8667-017C71CEE93B",
    "form_completion_date": "2015-3-12",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 106,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 197,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "efe8b105-b170-4679-8b97-c1142fefe069",
    "patient_ID": "TCGA.CD.8531",
    "bcr_drug_barcode": "TCGA-CD-8531-D70999",
    "bcr_drug_uuid": "8A235D07-A810-4162-B7CE-C45E5DC95658",
    "form_completion_date": "2015-3-12",
    "pharmaceutical_therapy_drug_name": "5-FLOUROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 106,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 197,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "c1cf00be-1a34-49aa-b1ab-6b2e26832c19",
    "patient_ID": "TCGA.CD.8533",
    "bcr_drug_barcode": "TCGA-CD-8533-D70959",
    "bcr_drug_uuid": "37E718D6-509F-4D7B-A3F0-306F9FB6E219",
    "form_completion_date": "2015-3-11",
    "pharmaceutical_therapy_drug_name": "CAPECITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 226,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 245,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "569dd23a-d0d7-409c-bc83-7340512f4195",
    "patient_ID": "TCGA.CD.8535",
    "bcr_drug_barcode": "TCGA-CD-8535-D70954",
    "bcr_drug_uuid": "F575C51D-7059-4E2D-A268-A13EE9363CA6",
    "form_completion_date": "2015-3-11",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 138,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 234,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "569dd23a-d0d7-409c-bc83-7340512f4195",
    "patient_ID": "TCGA.CD.8535",
    "bcr_drug_barcode": "TCGA-CD-8535-D70955",
    "bcr_drug_uuid": "60BEAD84-ACB8-4886-B19B-A0FFC0C9B55D",
    "form_completion_date": "2015-3-11",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 138,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 234,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "569dd23a-d0d7-409c-bc83-7340512f4195",
    "patient_ID": "TCGA.CD.8535",
    "bcr_drug_barcode": "TCGA-CD-8535-D70956",
    "bcr_drug_uuid": "6AADB438-9F15-45E6-8B23-AC64BB461799",
    "form_completion_date": "2015-3-11",
    "pharmaceutical_therapy_drug_name": "5-FLOUROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 138,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 234,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b2f6d8f3-3182-4e5e-be20-8470cfb832c5",
    "patient_ID": "TCGA.CD.8536",
    "bcr_drug_barcode": "TCGA-CD-8536-D70950",
    "bcr_drug_uuid": "FBAFB7D9-C8E3-4ABD-885D-D41C2667EB4A",
    "form_completion_date": "2015-3-11",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 54,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 135,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b2f6d8f3-3182-4e5e-be20-8470cfb832c5",
    "patient_ID": "TCGA.CD.8536",
    "bcr_drug_barcode": "TCGA-CD-8536-D70951",
    "bcr_drug_uuid": "F22F097F-3618-41DA-BB33-29F23C2EF4C0",
    "form_completion_date": "2015-3-11",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 54,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 135,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b2f6d8f3-3182-4e5e-be20-8470cfb832c5",
    "patient_ID": "TCGA.CD.8536",
    "bcr_drug_barcode": "TCGA-CD-8536-D70952",
    "bcr_drug_uuid": "C71F7C1C-FEED-41FF-AFEF-E0C54162B7EB",
    "form_completion_date": "2015-3-11",
    "pharmaceutical_therapy_drug_name": "CAPECITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 54,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 135,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "C63AE423-C90A-4CF4-AA42-653BB8FA3E69",
    "patient_ID": "TCGA.CD.A486",
    "bcr_drug_barcode": "TCGA-CD-A486-D58108",
    "bcr_drug_uuid": "C99A96B7-16A1-4C44-8941-9C047156BC2B",
    "form_completion_date": "2014-3-31",
    "pharmaceutical_therapy_drug_name": "TAXOL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 37,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 57,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "C63AE423-C90A-4CF4-AA42-653BB8FA3E69",
    "patient_ID": "TCGA.CD.A486",
    "bcr_drug_barcode": "TCGA-CD-A486-D58109",
    "bcr_drug_uuid": "DC5F1783-D6E6-447E-B491-1A0C0F74A4C3",
    "form_completion_date": "2014-3-31",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 37,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 57,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "C63AE423-C90A-4CF4-AA42-653BB8FA3E69",
    "patient_ID": "TCGA.CD.A486",
    "bcr_drug_barcode": "TCGA-CD-A486-D58110",
    "bcr_drug_uuid": "F5ED343B-469D-40F3-8845-D675CF3F9285",
    "form_completion_date": "2014-3-31",
    "pharmaceutical_therapy_drug_name": "CAPECITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 37,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 57,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "B7D2401E-7D64-4C89-A74C-16D634CAFE7F",
    "patient_ID": "TCGA.CD.A487",
    "bcr_drug_barcode": "TCGA-CD-A487-D58112",
    "bcr_drug_uuid": "2FE1DAEC-5BE5-495E-9136-FBBF6746937A",
    "form_completion_date": "2014-3-31",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 24,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 284,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "B7D2401E-7D64-4C89-A74C-16D634CAFE7F",
    "patient_ID": "TCGA.CD.A487",
    "bcr_drug_barcode": "TCGA-CD-A487-D58114",
    "bcr_drug_uuid": "D3FC6643-09AE-4E2F-8B86-FDFAB0DC24B6",
    "form_completion_date": "2014-3-31",
    "pharmaceutical_therapy_drug_name": "CAPECITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 24,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 284,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "B7D2401E-7D64-4C89-A74C-16D634CAFE7F",
    "patient_ID": "TCGA.CD.A487",
    "bcr_drug_barcode": "TCGA-CD-A487-D58113",
    "bcr_drug_uuid": "1D0FE4FC-5BBB-4762-B87A-B7E38932F709",
    "form_completion_date": "2014-3-31",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 24,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 284,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "A6635058-4498-463C-9BBC-1009DDA3308C",
    "patient_ID": "TCGA.CD.A48A",
    "bcr_drug_barcode": "TCGA-CD-A48A-D69717",
    "bcr_drug_uuid": "93546A16-CBD8-4220-9E86-B1D23E230E72",
    "form_completion_date": "2015-1-16",
    "pharmaceutical_therapy_drug_name": "CAPECITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 38,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 66,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "23451AB5-A32B-4EEC-9B8B-FD282282A0D4",
    "patient_ID": "TCGA.CD.A4MH",
    "bcr_drug_barcode": "TCGA-CD-A4MH-D69938",
    "bcr_drug_uuid": "F6BB0854-1B4F-4C68-AA1F-0936BB98BEC4",
    "form_completion_date": "2015-1-22",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 118,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 212,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "23451AB5-A32B-4EEC-9B8B-FD282282A0D4",
    "patient_ID": "TCGA.CD.A4MH",
    "bcr_drug_barcode": "TCGA-CD-A4MH-D69939",
    "bcr_drug_uuid": "1116B2BF-2E4C-4EA9-8DAE-8C4FA273BC3C",
    "form_completion_date": "2015-1-22",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 118,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 212,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "23451AB5-A32B-4EEC-9B8B-FD282282A0D4",
    "patient_ID": "TCGA.CD.A4MH",
    "bcr_drug_barcode": "TCGA-CD-A4MH-D69941",
    "bcr_drug_uuid": "6294FCF2-38E5-488E-A069-DAF2E23E63E8",
    "form_completion_date": "2015-1-22",
    "pharmaceutical_therapy_drug_name": "5-FLOUROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 118,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 212,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "287059FB-4E69-4D6D-99D5-91EC92D35BDE",
    "patient_ID": "TCGA.CD.A4MJ",
    "bcr_drug_barcode": "TCGA-CD-A4MJ-D69724",
    "bcr_drug_uuid": "90FA6E72-6EFD-4E99-B8BF-E8EBD4B07A3B",
    "form_completion_date": "2015-1-16",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 86,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 186,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "287059FB-4E69-4D6D-99D5-91EC92D35BDE",
    "patient_ID": "TCGA.CD.A4MJ",
    "bcr_drug_barcode": "TCGA-CD-A4MJ-D69727",
    "bcr_drug_uuid": "7AEEAF05-90E0-4978-ABB5-996550C4C75E",
    "form_completion_date": "2015-1-30",
    "pharmaceutical_therapy_drug_name": "5-FLOUROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 86,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 186,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "287059FB-4E69-4D6D-99D5-91EC92D35BDE",
    "patient_ID": "TCGA.CD.A4MJ",
    "bcr_drug_barcode": "TCGA-CD-A4MJ-D70218",
    "bcr_drug_uuid": "3D234948-2889-4BC9-A60E-FF7144CA9B31",
    "form_completion_date": "2015-1-30",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 86,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 186,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "e0e35051-fbb4-4389-aedb-87bde84d21ad",
    "patient_ID": "TCGA.CG.4305",
    "bcr_drug_barcode": "TCGA-CG-4305-D37560",
    "bcr_drug_uuid": "4FE50F2D-809A-4BCB-B02E-CC5155BDE7E6",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 607,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 669,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "e0e35051-fbb4-4389-aedb-87bde84d21ad",
    "patient_ID": "TCGA.CG.4305",
    "bcr_drug_barcode": "TCGA-CG-4305-D37561",
    "bcr_drug_uuid": "693829F4-9F41-4BBE-BD11-A194EF952C3F",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 607,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 699,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "e0e35051-fbb4-4389-aedb-87bde84d21ad",
    "patient_ID": "TCGA.CG.4305",
    "bcr_drug_barcode": "TCGA-CG-4305-D37562",
    "bcr_drug_uuid": "1491B5A4-ABEC-4743-94E5-7C70ADB82202",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "FOLINIC ACID",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 607,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 699,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5c087d33-0bd3-407d-8350-fabba6aec597",
    "patient_ID": "TCGA.CG.4444",
    "bcr_drug_barcode": "TCGA-CG-4444-D37563",
    "bcr_drug_uuid": "51475E4B-5DD7-44D3-95E4-647A56B55C04",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 92,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3c3d4ef0-019a-423e-89b2-4ac5a7b567ab",
    "patient_ID": "TCGA.CG.4460",
    "bcr_drug_barcode": "TCGA-CG-4460-D37564",
    "bcr_drug_uuid": "6216F809-3AD8-418D-847A-D67A7E879C36",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "CAPECITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 153,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3c3d4ef0-019a-423e-89b2-4ac5a7b567ab",
    "patient_ID": "TCGA.CG.4460",
    "bcr_drug_barcode": "TCGA-CG-4460-D37565",
    "bcr_drug_uuid": "F9D9E4EA-31E9-4DF5-A970-1AAC9AEED876",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 153,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3c3d4ef0-019a-423e-89b2-4ac5a7b567ab",
    "patient_ID": "TCGA.CG.4460",
    "bcr_drug_barcode": "TCGA-CG-4460-D37566",
    "bcr_drug_uuid": "A007C145-28E1-4292-8581-801186428A69",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "FOLINIC ACID",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 487,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 608,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3c3d4ef0-019a-423e-89b2-4ac5a7b567ab",
    "patient_ID": "TCGA.CG.4460",
    "bcr_drug_barcode": "TCGA-CG-4460-D37567",
    "bcr_drug_uuid": "CB78CAF9-7D16-458A-BA6B-4C74E7D107FF",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 487,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 608,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3c3d4ef0-019a-423e-89b2-4ac5a7b567ab",
    "patient_ID": "TCGA.CG.4460",
    "bcr_drug_barcode": "TCGA-CG-4460-D37568",
    "bcr_drug_uuid": "A95C258D-1B4A-4C04-81DC-98B72C417655",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 487,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 608,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "c9ab5bf4-092a-420f-9b90-87deea58104c",
    "patient_ID": "TCGA.CG.4465",
    "bcr_drug_barcode": "TCGA-CG-4465-D37569",
    "bcr_drug_uuid": "E2E02467-7B85-4A00-8C1C-CB2F0BACA297",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 62,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "c9ab5bf4-092a-420f-9b90-87deea58104c",
    "patient_ID": "TCGA.CG.4465",
    "bcr_drug_barcode": "TCGA-CG-4465-D37570",
    "bcr_drug_uuid": "AB89D7CB-8D38-4CFD-8B18-0A773E31FBF4",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 62,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "c9ab5bf4-092a-420f-9b90-87deea58104c",
    "patient_ID": "TCGA.CG.4465",
    "bcr_drug_barcode": "TCGA-CG-4465-D37571",
    "bcr_drug_uuid": "2249E9A6-E5CA-4DB1-BED0-9785DE7B460B",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "FOLINIC ACID",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 62,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2ac986f6-cd6f-4ca5-90cc-7a105cfe85ea",
    "patient_ID": "TCGA.CG.4469",
    "bcr_drug_barcode": "TCGA-CG-4469-D37572",
    "bcr_drug_uuid": "E5ECDA45-F458-4643-BF05-ABDBDFC96BDC",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 215,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2ac986f6-cd6f-4ca5-90cc-7a105cfe85ea",
    "patient_ID": "TCGA.CG.4469",
    "bcr_drug_barcode": "TCGA-CG-4469-D37573",
    "bcr_drug_uuid": "066A5F2D-2D5B-41C8-8AD9-29198D40DD26",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 215,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2ac986f6-cd6f-4ca5-90cc-7a105cfe85ea",
    "patient_ID": "TCGA.CG.4469",
    "bcr_drug_barcode": "TCGA-CG-4469-D37574",
    "bcr_drug_uuid": "7E6DEE4A-D635-4B08-8629-B6B66F49C16F",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "FOLINIC ACID",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 215,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "306f0222-8734-44ca-9a31-86e4e62b0a1b",
    "patient_ID": "TCGA.CG.4472",
    "bcr_drug_barcode": "TCGA-CG-4472-D37575",
    "bcr_drug_uuid": "0D337B25-42A4-4B8A-8C4A-199AF1C63554",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 122,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 273,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "306f0222-8734-44ca-9a31-86e4e62b0a1b",
    "patient_ID": "TCGA.CG.4472",
    "bcr_drug_barcode": "TCGA-CG-4472-D37576",
    "bcr_drug_uuid": "CE004927-8801-4AF6-87A9-1A71D9B9C7A6",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 122,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "306f0222-8734-44ca-9a31-86e4e62b0a1b",
    "patient_ID": "TCGA.CG.4472",
    "bcr_drug_barcode": "TCGA-CG-4472-D37577",
    "bcr_drug_uuid": "2D2FA687-5EE8-4384-BEB8-5D9771FED0EF",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "FOLINIC ACID",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 122,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "306f0222-8734-44ca-9a31-86e4e62b0a1b",
    "patient_ID": "TCGA.CG.4472",
    "bcr_drug_barcode": "TCGA-CG-4472-D37578",
    "bcr_drug_uuid": "213ACA82-DD48-442C-9B61-2545ECF33217",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "IRINOTECAN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 303,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "18d0aae7-9694-4252-b8fe-16e62dadab07",
    "patient_ID": "TCGA.CG.4477",
    "bcr_drug_barcode": "TCGA-CG-4477-D37579",
    "bcr_drug_uuid": "9B02C9BB-92BA-4E72-8B87-C52D3C233812",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 426,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 457,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "18d0aae7-9694-4252-b8fe-16e62dadab07",
    "patient_ID": "TCGA.CG.4477",
    "bcr_drug_barcode": "TCGA-CG-4477-D37580",
    "bcr_drug_uuid": "8F85533D-2939-417D-B5B0-1AB68FA71A11",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 426,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 457,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "bdc3899e-15ae-421f-829b-0e07fbd27c60",
    "patient_ID": "TCGA.CG.5717",
    "bcr_drug_barcode": "TCGA-CG-5717-D37581",
    "bcr_drug_uuid": "E8A29207-AB7D-40CD-888D-29BBAA62AE93",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 151,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 212,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "bdc3899e-15ae-421f-829b-0e07fbd27c60",
    "patient_ID": "TCGA.CG.5717",
    "bcr_drug_barcode": "TCGA-CG-5717-D37582",
    "bcr_drug_uuid": "83198ACC-3ABA-46A0-BD76-E83B633E034B",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 151,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 212,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "bdc3899e-15ae-421f-829b-0e07fbd27c60",
    "patient_ID": "TCGA.CG.5717",
    "bcr_drug_barcode": "TCGA-CG-5717-D37583",
    "bcr_drug_uuid": "ECAD283C-296E-408E-B401-1B06C531253A",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "FOLINIC ACID",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 151,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 212,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0b4e8d73-459d-4930-9d1a-abb8d53e1844",
    "patient_ID": "TCGA.CG.5724",
    "bcr_drug_barcode": "TCGA-CG-5724-D37584",
    "bcr_drug_uuid": "ADDADFDC-26FB-43B1-AAA7-D38323D40063",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 153,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 305,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "129d95ca-71ef-44aa-a93d-f87803c37c9a",
    "patient_ID": "TCGA.CG.5725",
    "bcr_drug_barcode": "TCGA-CG-5725-D37585",
    "bcr_drug_uuid": "C75FFCB1-97DF-4D25-9129-5739E83D3172",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "129d95ca-71ef-44aa-a93d-f87803c37c9a",
    "patient_ID": "TCGA.CG.5725",
    "bcr_drug_barcode": "TCGA-CG-5725-D37586",
    "bcr_drug_uuid": "3FF1A034-1B02-4F39-828B-CA8D8CCF045D",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "129d95ca-71ef-44aa-a93d-f87803c37c9a",
    "patient_ID": "TCGA.CG.5725",
    "bcr_drug_barcode": "TCGA-CG-5725-D37587",
    "bcr_drug_uuid": "F88EE3CF-8DE0-4FF5-B03D-FF90EFFA1FE1",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "FOLINIC ACID",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "129d95ca-71ef-44aa-a93d-f87803c37c9a",
    "patient_ID": "TCGA.CG.5725",
    "bcr_drug_barcode": "TCGA-CG-5725-D37588",
    "bcr_drug_uuid": "A7A83AA9-3E61-4233-ACE2-366DAA7ED6F7",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 334,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 334,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "129d95ca-71ef-44aa-a93d-f87803c37c9a",
    "patient_ID": "TCGA.CG.5725",
    "bcr_drug_barcode": "TCGA-CG-5725-D37589",
    "bcr_drug_uuid": "9E38E9CB-FA44-4B04-835D-829AC5CB50B4",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "CETUXIMAB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "e62d5f3c-0a99-4932-a589-bff4fa02b1d3",
    "patient_ID": "TCGA.CG.5732",
    "bcr_drug_barcode": "TCGA-CG-5732-D37590",
    "bcr_drug_uuid": "609D8C85-26DE-432C-9FE0-E18EAA150E2A",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "MITOMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 366,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 427,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "e62d5f3c-0a99-4932-a589-bff4fa02b1d3",
    "patient_ID": "TCGA.CG.5732",
    "bcr_drug_barcode": "TCGA-CG-5732-D37591",
    "bcr_drug_uuid": "D14745F0-59EE-45E0-A1FA-25700BC24934",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1949,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2070,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "e62d5f3c-0a99-4932-a589-bff4fa02b1d3",
    "patient_ID": "TCGA.CG.5732",
    "bcr_drug_barcode": "TCGA-CG-5732-D37592",
    "bcr_drug_uuid": "778332E6-A480-4F21-AB69-BB6BDEE373F4",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "FOLINIC ACID",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1949,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2070,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "e62d5f3c-0a99-4932-a589-bff4fa02b1d3",
    "patient_ID": "TCGA.CG.5732",
    "bcr_drug_barcode": "TCGA-CG-5732-D37593",
    "bcr_drug_uuid": "83DEEF80-C1C0-4AFF-B8E8-F37541ADE93A",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1949,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2070,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "e62d5f3c-0a99-4932-a589-bff4fa02b1d3",
    "patient_ID": "TCGA.CG.5732",
    "bcr_drug_barcode": "TCGA-CG-5732-D37594",
    "bcr_drug_uuid": "1387F8E8-9C86-49C8-A102-24354B63F116",
    "form_completion_date": "2012-12-4",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 2070,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2070,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2dc154aa-c478-404b-a92e-86abcc8dbdb7",
    "patient_ID": "TCGA.D7.5577",
    "bcr_drug_barcode": "TCGA-D7-5577-D13821",
    "bcr_drug_uuid": "eddf6027-36e4-4eb1-b4ab-59e0455453b9",
    "form_completion_date": "2011-6-20",
    "pharmaceutical_therapy_drug_name": "CALCIUM FOLIATUM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 81,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_units": "MG",
    "drug_dose": 420,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "2dc154aa-c478-404b-a92e-86abcc8dbdb7",
    "patient_ID": "TCGA.D7.5577",
    "bcr_drug_barcode": "TCGA-D7-5577-D64886",
    "bcr_drug_uuid": "98146EC0-9226-4EF2-8DFA-743CB1624292",
    "form_completion_date": "2014-9-15",
    "pharmaceutical_therapy_drug_name": "CISPLATINUM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 81,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2dc154aa-c478-404b-a92e-86abcc8dbdb7",
    "patient_ID": "TCGA.D7.5577",
    "bcr_drug_barcode": "TCGA-D7-5577-D64887",
    "bcr_drug_uuid": "651EAE70-461F-4656-8059-B1C08352CA23",
    "form_completion_date": "2014-9-15",
    "pharmaceutical_therapy_drug_name": "EPIRUBICINUM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 81,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2dc154aa-c478-404b-a92e-86abcc8dbdb7",
    "patient_ID": "TCGA.D7.5577",
    "bcr_drug_barcode": "TCGA-D7-5577-D64888",
    "bcr_drug_uuid": "6DFABED0-E03E-4089-8102-46E2AB77A61F",
    "form_completion_date": "2014-9-15",
    "pharmaceutical_therapy_drug_name": "FLUOROURACILUM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 81,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8b5746f9-dbee-40bd-9141-1081960cf286",
    "patient_ID": "TCGA.D7.5579",
    "bcr_drug_barcode": "TCGA-D7-5579-D13826",
    "bcr_drug_uuid": "ef5c0d63-f405-4a85-844f-795ddb9e8555",
    "form_completion_date": "2011-7-11",
    "pharmaceutical_therapy_drug_name": "CALCIUM FOLIATUM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 25,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 307,
    "drug_cycles": 5,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "8b5746f9-dbee-40bd-9141-1081960cf286",
    "patient_ID": "TCGA.D7.5579",
    "bcr_drug_barcode": "TCGA-D7-5579-D64890",
    "bcr_drug_uuid": "C60400A7-C7F8-4082-A60C-92B4B940C8DF",
    "form_completion_date": "2014-9-15",
    "pharmaceutical_therapy_drug_name": "ETC POSIDUM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 25,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 307,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8b5746f9-dbee-40bd-9141-1081960cf286",
    "patient_ID": "TCGA.D7.5579",
    "bcr_drug_barcode": "TCGA-D7-5579-D64891",
    "bcr_drug_uuid": "64A6FCD0-2466-494F-8272-A6CC99061B9F",
    "form_completion_date": "2014-9-15",
    "pharmaceutical_therapy_drug_name": "FLUOROURACILUM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 25,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 307,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "e37cae9e-0656-4b89-b326-739a5cc859e0",
    "patient_ID": "TCGA.D7.6519",
    "bcr_drug_barcode": "TCGA-D7-6519-D28942",
    "bcr_drug_uuid": "7b1d3fbd-a2f3-4950-94ed-2e01f7943809",
    "form_completion_date": "2012-3-2",
    "pharmaceutical_therapy_drug_name": "5-FU+ ETOPOSIDIUM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 503,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_cycles": 2,
    "drug_units": "MG/M2",
    "drug_tota_dose_units": "MG",
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PALLIATIVE"
  },
  {
    "bcr_patient_uuid": "e37cae9e-0656-4b89-b326-739a5cc859e0",
    "patient_ID": "TCGA.D7.6519",
    "bcr_drug_barcode": "TCGA-D7-6519-D28941",
    "bcr_drug_uuid": "0e1ae485-c9c4-4665-a77b-2a9b69122808",
    "form_completion_date": "2012-3-2",
    "pharmaceutical_therapy_drug_name": "5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 55,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 237,
    "drug_cycles": 6,
    "drug_units": "MG/M2",
    "drug_tota_dose_units": "MG",
    "drug_dose": 425,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 19700
  },
  {
    "bcr_patient_uuid": "3c573af6-6298-49de-8de0-6a7f9ce9b000",
    "patient_ID": "TCGA.D7.6520",
    "bcr_drug_barcode": "TCGA-D7-6520-D28620",
    "bcr_drug_uuid": "aab4cab8-a128-4320-84d3-ce1829173002",
    "form_completion_date": "2012-3-1",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 53,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 172,
    "drug_cycles": 6,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 87.5,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "3c573af6-6298-49de-8de0-6a7f9ce9b000",
    "patient_ID": "TCGA.D7.6520",
    "bcr_drug_barcode": "TCGA-D7-6520-D34561",
    "bcr_drug_uuid": "9AE50E97-7268-45C0-8619-DA5B94299BCC",
    "form_completion_date": "2012-8-23",
    "pharmaceutical_therapy_drug_name": "CISPLATINUM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 249,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 321,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3c573af6-6298-49de-8de0-6a7f9ce9b000",
    "patient_ID": "TCGA.D7.6520",
    "bcr_drug_barcode": "TCGA-D7-6520-D64894",
    "bcr_drug_uuid": "2311DC1E-90DB-488A-8726-9B879BA1FC50",
    "form_completion_date": "2014-9-15",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 53,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 172,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3c573af6-6298-49de-8de0-6a7f9ce9b000",
    "patient_ID": "TCGA.D7.6520",
    "bcr_drug_barcode": "TCGA-D7-6520-D64895",
    "bcr_drug_uuid": "895FC5D5-B15E-475A-BEC8-A98B3CD688F0",
    "form_completion_date": "2014-9-15",
    "pharmaceutical_therapy_drug_name": "CAPECYTABINUM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 53,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 172,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3c573af6-6298-49de-8de0-6a7f9ce9b000",
    "patient_ID": "TCGA.D7.6520",
    "bcr_drug_barcode": "TCGA-D7-6520-D64896",
    "bcr_drug_uuid": "BB3A3B0B-8AE9-49DE-8C28-791F348F2375",
    "form_completion_date": "2014-9-15",
    "pharmaceutical_therapy_drug_name": "DEXAMETHASONE PHOSPHATE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 249,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 321,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3c573af6-6298-49de-8de0-6a7f9ce9b000",
    "patient_ID": "TCGA.D7.6520",
    "bcr_drug_barcode": "TCGA-D7-6520-D64897",
    "bcr_drug_uuid": "2A244617-5F9F-456C-9358-C96486AA3678",
    "form_completion_date": "2014-9-15",
    "pharmaceutical_therapy_drug_name": "DOCETAXELUM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 249,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 321,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3c573af6-6298-49de-8de0-6a7f9ce9b000",
    "patient_ID": "TCGA.D7.6520",
    "bcr_drug_barcode": "TCGA-D7-6520-D64898",
    "bcr_drug_uuid": "AB5C6559-7F18-4F29-BBBB-3E8E18B8562A",
    "form_completion_date": "2014-9-15",
    "pharmaceutical_therapy_drug_name": "FLUOROURACILUM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 249,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 321,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6de6b8e2-03eb-4f32-b5a3-bea73fc632b4",
    "patient_ID": "TCGA.D7.6521",
    "bcr_drug_barcode": "TCGA-D7-6521-D22135",
    "bcr_drug_uuid": "2ce02f78-bf40-48d6-aedf-8989180c0249",
    "form_completion_date": "2012-2-24",
    "pharmaceutical_therapy_drug_name": "PLFE/FLO",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 29,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_tota_dose_units": "MG",
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "82f9a197-040d-4c5e-89d9-d87a7aa0168d",
    "patient_ID": "TCGA.D7.6525",
    "bcr_drug_barcode": "TCGA-D7-6525-D22131",
    "bcr_drug_uuid": "f522f3c0-8d56-404a-93b6-d2bc05b46882",
    "form_completion_date": "2012-2-24",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 64,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 153,
    "drug_route": "INHALATION",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "a28e57e2-9071-4558-856a-162f7a837380",
    "patient_ID": "TCGA.D7.6526",
    "bcr_drug_barcode": "TCGA-D7-6526-D28637",
    "bcr_drug_uuid": "c86e071b-6d28-4e4a-8ed0-4736ed7e76b6",
    "form_completion_date": "2012-2-27",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 74,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_units": "MG",
    "drug_dose": 30,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "a28e57e2-9071-4558-856a-162f7a837380",
    "patient_ID": "TCGA.D7.6526",
    "bcr_drug_barcode": "TCGA-D7-6526-D68505",
    "bcr_drug_uuid": "97BD1807-DD7A-4441-9770-A65C2B13141D",
    "form_completion_date": "2014-11-21",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 74,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "a28e57e2-9071-4558-856a-162f7a837380",
    "patient_ID": "TCGA.D7.6526",
    "bcr_drug_barcode": "TCGA-D7-6526-D68506",
    "bcr_drug_uuid": "0D17995B-DDE2-40F5-B3AB-356E1E1CBFE0",
    "form_completion_date": "2014-11-21",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 74,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "a28e57e2-9071-4558-856a-162f7a837380",
    "patient_ID": "TCGA.D7.6526",
    "bcr_drug_barcode": "TCGA-D7-6526-D68507",
    "bcr_drug_uuid": "52EF598C-05F4-469A-B16D-DEC7FA6180A3",
    "form_completion_date": "2014-11-21",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 74,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "cb622cd6-776d-4681-8a67-4addd61c66b8",
    "patient_ID": "TCGA.D7.6527",
    "bcr_drug_barcode": "TCGA-D7-6527-D22129",
    "bcr_drug_uuid": "336b311b-1e0b-47d8-b413-6ac99efb7866",
    "form_completion_date": "2012-2-24",
    "pharmaceutical_therapy_drug_name": "5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 55,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 116,
    "drug_units": "MG",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "cb622cd6-776d-4681-8a67-4addd61c66b8",
    "patient_ID": "TCGA.D7.6527",
    "bcr_drug_barcode": "TCGA-D7-6527-D64900",
    "bcr_drug_uuid": "D022D4CD-92DA-41FE-AC88-6E0D039B4685",
    "form_completion_date": "2014-9-15",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 55,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 116,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6ffefb3f-3919-4fef-ab15-5d32d8f51d57",
    "patient_ID": "TCGA.D7.6817",
    "bcr_drug_barcode": "TCGA-D7-6817-D29919",
    "bcr_drug_uuid": "B1CC29BE-67A0-42D9-8E2E-C97DB9E46E5D",
    "form_completion_date": "2012-3-30",
    "pharmaceutical_therapy_drug_name": "5 FLUOROURACILUM+LEUCOVORIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 32,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 144,
    "drug_cycles": 5,
    "drug_units": "MG/M2",
    "drug_tota_dose_units": "MG",
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "aa2934f9-8783-428e-88a6-1d04b93fa1fd",
    "patient_ID": "TCGA.D7.6818",
    "bcr_drug_barcode": "TCGA-D7-6818-D29925",
    "bcr_drug_uuid": "634e2d9f-675b-4944-b726-547fae43ec45",
    "form_completion_date": "2012-3-26",
    "pharmaceutical_therapy_drug_name": "5 FLUOROURACILUM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 63,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 201,
    "drug_cycles": 5,
    "drug_units": "MG/M2",
    "drug_tota_dose_units": "MG",
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "aa2934f9-8783-428e-88a6-1d04b93fa1fd",
    "patient_ID": "TCGA.D7.6818",
    "bcr_drug_barcode": "TCGA-D7-6818-D64902",
    "bcr_drug_uuid": "F10460B9-50CB-4721-800C-F7A800D6B78A",
    "form_completion_date": "2014-9-15",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 63,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 201,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1e1cdf72-820f-48a4-8fb6-89575d07cde9",
    "patient_ID": "TCGA.D7.8570",
    "bcr_drug_barcode": "TCGA-D7-8570-D51359",
    "bcr_drug_uuid": "898BBEFE-3CF8-4397-A77F-BE0D73CD7880",
    "form_completion_date": "2013-11-18",
    "pharmaceutical_therapy_drug_name": "PLFE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 36,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 243,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "81a7f6a2-e44c-43d6-b687-01158eaf44ee",
    "patient_ID": "TCGA.D7.8579",
    "bcr_drug_barcode": "TCGA-D7-8579-D52679",
    "bcr_drug_uuid": "F6774DC9-E844-4EF4-BD30-965D1E0FDEB6",
    "form_completion_date": "2013-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACILUM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 97,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 213,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "32B44138-64E2-4BBF-AA2F-93A3B07EC670",
    "patient_ID": "TCGA.D7.A4YU",
    "bcr_drug_barcode": "TCGA-D7-A4YU-D39493",
    "bcr_drug_uuid": "752A76A3-A84A-45F3-9F63-F0250162D9E4",
    "form_completion_date": "2013-1-24",
    "pharmaceutical_therapy_drug_name": "CAPECITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 213,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "32B44138-64E2-4BBF-AA2F-93A3B07EC670",
    "patient_ID": "TCGA.D7.A4YU",
    "bcr_drug_barcode": "TCGA-D7-A4YU-D51364",
    "bcr_drug_uuid": "67F00099-548F-4B1F-A3DD-076ECFB4DA78",
    "form_completion_date": "2013-11-18",
    "pharmaceutical_therapy_drug_name": "FLC",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 518,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "17F63789-2EE3-4CD9-9273-5FA73662DB39",
    "patient_ID": "TCGA.D7.A4YY",
    "bcr_drug_barcode": "TCGA-D7-A4YY-D39757",
    "bcr_drug_uuid": "54D75973-D9DB-40AA-B9FA-473BDC76FD2B",
    "form_completion_date": "2013-2-1",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 40,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "DCE21359-004F-4E8B-89E4-9E1A30FAFFDF",
    "patient_ID": "TCGA.D7.A4Z0",
    "bcr_drug_barcode": "TCGA-D7-A4Z0-D39754",
    "bcr_drug_uuid": "DF769626-0FDC-4069-B1E6-32078AE6366B",
    "form_completion_date": "2013-2-1",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACILUM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 72,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "37F93D19-C78F-4FBC-AFFB-5A2CCC84BE1B",
    "patient_ID": "TCGA.D7.A747",
    "bcr_drug_barcode": "TCGA-D7-A747-D58326",
    "bcr_drug_uuid": "329B574E-FD62-402C-BAB1-1B86157ABB42",
    "form_completion_date": "2014-4-7",
    "pharmaceutical_therapy_drug_name": "EPIRUBICINUM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 85,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 208,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "37F93D19-C78F-4FBC-AFFB-5A2CCC84BE1B",
    "patient_ID": "TCGA.D7.A747",
    "bcr_drug_barcode": "TCGA-D7-A747-D61636",
    "bcr_drug_uuid": "4A0774C6-70B3-4A03-8DE5-46E3F0FEC975",
    "form_completion_date": "2014-7-2",
    "pharmaceutical_therapy_drug_name": "CISPLATINUM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 85,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 208,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "37F93D19-C78F-4FBC-AFFB-5A2CCC84BE1B",
    "patient_ID": "TCGA.D7.A747",
    "bcr_drug_barcode": "TCGA-D7-A747-D61639",
    "bcr_drug_uuid": "19AF3680-BE81-43D4-9667-36FA05D0F8AB",
    "form_completion_date": "2014-7-2",
    "pharmaceutical_therapy_drug_name": "CAPECYTABINUM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 85,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 208,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BF0F1735-F94D-4B82-8F91-2FD2BAC80E32",
    "patient_ID": "TCGA.D7.A748",
    "bcr_drug_barcode": "TCGA-D7-A748-D58331",
    "bcr_drug_uuid": "D328BEA0-529E-4E17-B022-5A1C459086C9",
    "form_completion_date": "2014-4-7",
    "pharmaceutical_therapy_drug_name": "EPIRUBICINUM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 104,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 104,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BF0F1735-F94D-4B82-8F91-2FD2BAC80E32",
    "patient_ID": "TCGA.D7.A748",
    "bcr_drug_barcode": "TCGA-D7-A748-D58330",
    "bcr_drug_uuid": "11C1813D-4CA0-4DC8-A02D-BDAE40E1420D",
    "form_completion_date": "2014-4-7",
    "pharmaceutical_therapy_drug_name": "5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 40,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 72,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BF0F1735-F94D-4B82-8F91-2FD2BAC80E32",
    "patient_ID": "TCGA.D7.A748",
    "bcr_drug_barcode": "TCGA-D7-A748-D61641",
    "bcr_drug_uuid": "4EF5718C-A697-461C-9D3C-1B49F9F263EA",
    "form_completion_date": "2014-7-2",
    "pharmaceutical_therapy_drug_name": "OXALIPLATINUM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 104,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 104,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BF0F1735-F94D-4B82-8F91-2FD2BAC80E32",
    "patient_ID": "TCGA.D7.A748",
    "bcr_drug_barcode": "TCGA-D7-A748-D61642",
    "bcr_drug_uuid": "9A645470-B657-41A6-8022-AFD121297378",
    "form_completion_date": "2014-7-2",
    "pharmaceutical_therapy_drug_name": "CAPECYTABINUM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 104,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 104,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4e921bc8-df5d-4f54-93d1-d5a433f91bdb",
    "patient_ID": "TCGA.EQ.8122",
    "bcr_drug_barcode": "TCGA-EQ-8122-D32951",
    "bcr_drug_uuid": "9E669396-FE81-4E4B-A481-2654384F83DA",
    "form_completion_date": "2012-6-18",
    "pharmaceutical_therapy_drug_name": "5FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 68,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 157,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4e921bc8-df5d-4f54-93d1-d5a433f91bdb",
    "patient_ID": "TCGA.EQ.8122",
    "bcr_drug_barcode": "TCGA-EQ-8122-D32954",
    "bcr_drug_uuid": "4D38CD6C-6B2E-477A-B670-69BE7E48425E",
    "form_completion_date": "2012-6-18",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 68,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 157,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "FE1AD544-3189-4495-86BE-0C68F3234238",
    "patient_ID": "TCGA.EQ.A4SO",
    "bcr_drug_barcode": "TCGA-EQ-A4SO-D51270",
    "bcr_drug_uuid": "CD2B70A6-F1A4-4942-9F77-049AFAE3DE45",
    "form_completion_date": "2013-11-14",
    "pharmaceutical_therapy_drug_name": "CAPECITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 83,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 300,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "FE1AD544-3189-4495-86BE-0C68F3234238",
    "patient_ID": "TCGA.EQ.A4SO",
    "bcr_drug_barcode": "TCGA-EQ-A4SO-D51273",
    "bcr_drug_uuid": "9572BB9B-E0A8-4CFA-8169-361391E2F556",
    "form_completion_date": "2013-11-14",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 83,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 300,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "FE1AD544-3189-4495-86BE-0C68F3234238",
    "patient_ID": "TCGA.EQ.A4SO",
    "bcr_drug_barcode": "TCGA-EQ-A4SO-D51280",
    "bcr_drug_uuid": "EDDFA66F-3E02-4268-9B87-2D5795D6F20B",
    "form_completion_date": "2013-11-14",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 179,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 222,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "CCA74404-CD91-4A69-AE09-BFB5D9142D3D",
    "patient_ID": "TCGA.F1.A448",
    "bcr_drug_barcode": "TCGA-F1-A448-D36509",
    "bcr_drug_uuid": "FDD21475-195B-4A98-A73F-93B1AB0DF95E",
    "form_completion_date": "2012-10-31",
    "pharmaceutical_therapy_drug_name": "CAPECITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 98,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 119,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "CCA74404-CD91-4A69-AE09-BFB5D9142D3D",
    "patient_ID": "TCGA.F1.A448",
    "bcr_drug_barcode": "TCGA-F1-A448-D36510",
    "bcr_drug_uuid": "F8F5A539-3E12-4643-BB34-E6ADCCC2E2D1",
    "form_completion_date": "2012-10-31",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 98,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 119,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "CCA74404-CD91-4A69-AE09-BFB5D9142D3D",
    "patient_ID": "TCGA.F1.A448",
    "bcr_drug_barcode": "TCGA-F1-A448-D36511",
    "bcr_drug_uuid": "2E8456F0-6FFA-4F5D-9F69-D77692059B4A",
    "form_completion_date": "2012-10-31",
    "pharmaceutical_therapy_drug_name": "5FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 161,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 175,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5C76CB89-B1B1-4910-B811-E44D3B277430",
    "patient_ID": "TCGA.F1.A72C",
    "bcr_drug_barcode": "TCGA-F1-A72C-D53060",
    "bcr_drug_uuid": "2170E1D0-F575-410D-A6A1-0810B07B47E1",
    "form_completion_date": "2013-12-9",
    "pharmaceutical_therapy_drug_name": "CAPECITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 166,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 181,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "45aacbb4-0fd8-431c-a57b-279ea57a19fc",
    "patient_ID": "TCGA.FP.7829",
    "bcr_drug_barcode": "TCGA-FP-7829-D44169",
    "bcr_drug_uuid": "851E73E0-FBF1-41E9-B49D-05DC1E0F5BD2",
    "form_completion_date": "2013-6-14",
    "pharmaceutical_therapy_drug_name": "5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 53,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 85,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "d384dd0c-1947-4ffc-bee9-de38311d8249",
    "patient_ID": "TCGA.FP.7916",
    "bcr_drug_barcode": "TCGA-FP-7916-D46168",
    "bcr_drug_uuid": "7496D73B-36AF-4253-ACFE-F45CBA69BC4A",
    "form_completion_date": "2013-8-2",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 108,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 142,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b2e2d35c-7a79-4165-97a5-82d5c37d94f2",
    "patient_ID": "TCGA.FP.7998",
    "bcr_drug_barcode": "TCGA-FP-7998-D46164",
    "bcr_drug_uuid": "23CA0289-C7D4-452E-9D12-140A908B6A89",
    "form_completion_date": "2013-8-2",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 168,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 501,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b2e2d35c-7a79-4165-97a5-82d5c37d94f2",
    "patient_ID": "TCGA.FP.7998",
    "bcr_drug_barcode": "TCGA-FP-7998-D46165",
    "bcr_drug_uuid": "C2CB4B51-3622-45B8-AABD-79F98468E09B",
    "form_completion_date": "2013-8-2",
    "pharmaceutical_therapy_drug_name": "5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 168,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 501,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "233cb00f-b470-47fb-ad93-2a1597655ed6",
    "patient_ID": "TCGA.FP.8209",
    "bcr_drug_barcode": "TCGA-FP-8209-D32948",
    "bcr_drug_uuid": "AE7DED9A-F501-4686-AAF2-85D5C096A93C",
    "form_completion_date": "2012-6-17",
    "pharmaceutical_therapy_drug_name": "5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "233cb00f-b470-47fb-ad93-2a1597655ed6",
    "patient_ID": "TCGA.FP.8209",
    "bcr_drug_barcode": "TCGA-FP-8209-D32949",
    "bcr_drug_uuid": "7BB42B9B-770C-4432-81A5-F2047CC83293",
    "form_completion_date": "2012-6-17",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "92654ad8-156c-4dd1-862e-dc339240d721",
    "patient_ID": "TCGA.FP.8210",
    "bcr_drug_barcode": "TCGA-FP-8210-D32936",
    "bcr_drug_uuid": "59E3DAAA-12B0-4EDF-81BA-6E4F54B73A39",
    "form_completion_date": "2012-6-16",
    "pharmaceutical_therapy_drug_name": "5FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 62,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "92654ad8-156c-4dd1-862e-dc339240d721",
    "patient_ID": "TCGA.FP.8210",
    "bcr_drug_barcode": "TCGA-FP-8210-D32937",
    "bcr_drug_uuid": "985A6C89-6AB8-4056-9E7C-E006C0272562",
    "form_completion_date": "2012-6-16",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 62,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "92654ad8-156c-4dd1-862e-dc339240d721",
    "patient_ID": "TCGA.FP.8210",
    "bcr_drug_barcode": "TCGA-FP-8210-D32938",
    "bcr_drug_uuid": "EC0BDDF1-693E-4E39-AFFD-8006DFDB4568",
    "form_completion_date": "2012-6-16",
    "pharmaceutical_therapy_drug_name": "VP-16",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 62,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0b1663fc-6a7e-4698-951d-a8c90fdf2411",
    "patient_ID": "TCGA.FP.8211",
    "bcr_drug_barcode": "TCGA-FP-8211-D44176",
    "bcr_drug_uuid": "34AF3A1E-1369-4474-94F4-685DA61EE187",
    "form_completion_date": "2013-6-14",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 110,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 357,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0b1663fc-6a7e-4698-951d-a8c90fdf2411",
    "patient_ID": "TCGA.FP.8211",
    "bcr_drug_barcode": "TCGA-FP-8211-D44177",
    "bcr_drug_uuid": "05D02386-6DA2-4F5F-BDF2-3A989E33430E",
    "form_completion_date": "2013-6-14",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 110,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 279,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "48ABE0EF-DFD5-4E36-A319-C4EC3165CBA1",
    "patient_ID": "TCGA.FP.A4BE",
    "bcr_drug_barcode": "TCGA-FP-A4BE-D44166",
    "bcr_drug_uuid": "33A9FF03-438A-46B5-A15B-36C039BA77E8",
    "form_completion_date": "2013-6-14",
    "pharmaceutical_therapy_drug_name": "5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 102,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 239,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "36ABEAF9-CC0F-43DD-9C55-B9347D826529",
    "patient_ID": "TCGA.FP.A9TM",
    "bcr_drug_barcode": "TCGA-FP-A9TM-D72124",
    "bcr_drug_uuid": "D440BC94-9385-41B6-9453-459F1BDD926D",
    "form_completion_date": "2015-4-16",
    "pharmaceutical_therapy_drug_name": "5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 110,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 142,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "36ABEAF9-CC0F-43DD-9C55-B9347D826529",
    "patient_ID": "TCGA.FP.A9TM",
    "bcr_drug_barcode": "TCGA-FP-A9TM-D72125",
    "bcr_drug_uuid": "7B0A2628-C09F-4800-8785-084F66AB61C3",
    "form_completion_date": "2015-4-16",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 110,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 142,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "06fd3086-0801-4d74-bced-4916efc544d2",
    "patient_ID": "TCGA.HF.7131",
    "bcr_drug_barcode": "TCGA-HF-7131-D19158",
    "bcr_drug_uuid": "7e17cfc1-d4de-46e6-aac8-27d5f48bb252",
    "form_completion_date": "2011-11-17",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "drug_cycles": 5,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 40,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "06fd3086-0801-4d74-bced-4916efc544d2",
    "patient_ID": "TCGA.HF.7131",
    "bcr_drug_barcode": "TCGA-HF-7131-D19156",
    "bcr_drug_uuid": "1d22a7fe-ae11-4eb8-bcb2-edc28ac33767",
    "form_completion_date": "2011-11-17",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "drug_cycles": 5,
    "drug_units": "MG",
    "drug_dose": 820,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "6c3687fd-0761-477d-95ab-73e11d66dbd6",
    "patient_ID": "TCGA.HF.7132",
    "bcr_drug_barcode": "TCGA-HF-7132-D18988",
    "bcr_drug_uuid": "6c7c0974-bacc-44ca-a3cf-1990f0fc312a",
    "form_completion_date": "2011-11-17",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "drug_cycles": 5,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 180,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 782
  },
  {
    "bcr_patient_uuid": "6c3687fd-0761-477d-95ab-73e11d66dbd6",
    "patient_ID": "TCGA.HF.7132",
    "bcr_drug_barcode": "TCGA-HF-7132-D19149",
    "bcr_drug_uuid": "bf9ab4ae-7a81-4b17-92ca-da04056812ec",
    "form_completion_date": "2011-11-17",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "drug_cycles": 5,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 3785,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 16841
  },
  {
    "bcr_patient_uuid": "6c3687fd-0761-477d-95ab-73e11d66dbd6",
    "patient_ID": "TCGA.HF.7132",
    "bcr_drug_barcode": "TCGA-HF-7132-D71171",
    "bcr_drug_uuid": "D0BDFBB9-91FB-450C-92EA-23200E973F03",
    "form_completion_date": "2015-3-19",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 75,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 208,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5d33895e-a959-4d5e-8850-c49c7fa49a22",
    "patient_ID": "TCGA.HF.7133",
    "bcr_drug_barcode": "TCGA-HF-7133-D18983",
    "bcr_drug_uuid": "1f750598-b418-450c-8fbf-af16210ac770",
    "form_completion_date": "2011-11-22",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "drug_cycles": 2,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 347,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 2429
  },
  {
    "bcr_patient_uuid": "5d33895e-a959-4d5e-8850-c49c7fa49a22",
    "patient_ID": "TCGA.HF.7133",
    "bcr_drug_barcode": "TCGA-HF-7133-D18979",
    "bcr_drug_uuid": "60a0c2ba-79bd-4752-9060-1cd75c817208",
    "form_completion_date": "2011-11-22",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "drug_cycles": 1,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 87,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 87
  },
  {
    "bcr_patient_uuid": "5d33895e-a959-4d5e-8850-c49c7fa49a22",
    "patient_ID": "TCGA.HF.7133",
    "bcr_drug_barcode": "TCGA-HF-7133-D19150",
    "bcr_drug_uuid": "84bd34c7-66c5-4a08-b3e3-5204cdc8ee4a",
    "form_completion_date": "2011-11-22",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "drug_cycles": 1,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 104,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 104
  },
  {
    "bcr_patient_uuid": "5d33895e-a959-4d5e-8850-c49c7fa49a22",
    "patient_ID": "TCGA.HF.7133",
    "bcr_drug_barcode": "TCGA-HF-7133-D71173",
    "bcr_drug_uuid": "0AD2FBA9-19EC-42E8-AB22-AC6123BD30EA",
    "form_completion_date": "2015-3-19",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 85,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 85,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5d33895e-a959-4d5e-8850-c49c7fa49a22",
    "patient_ID": "TCGA.HF.7133",
    "bcr_drug_barcode": "TCGA-HF-7133-D71174",
    "bcr_drug_uuid": "C485E281-5953-4A1B-A038-6617D21687F5",
    "form_completion_date": "2015-3-19",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 85,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 85,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5d33895e-a959-4d5e-8850-c49c7fa49a22",
    "patient_ID": "TCGA.HF.7133",
    "bcr_drug_barcode": "TCGA-HF-7133-D71175",
    "bcr_drug_uuid": "D519FBFC-8AF0-40DA-B7BD-C197D2B78E29",
    "form_completion_date": "2015-3-19",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 85,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 141,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "647dc54f-a51b-40ea-9d97-c93598c2af71",
    "patient_ID": "TCGA.HF.7136",
    "bcr_drug_barcode": "TCGA-HF-7136-D18756",
    "bcr_drug_uuid": "6bd8740e-141a-4370-adb2-ce0dceb03bf7",
    "form_completion_date": "2011-11-17",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "drug_cycles": 4,
    "drug_units": "MG/DAY",
    "drug_tota_dose_units": "MG",
    "drug_dose": 40,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 680
  },
  {
    "bcr_patient_uuid": "647dc54f-a51b-40ea-9d97-c93598c2af71",
    "patient_ID": "TCGA.HF.7136",
    "bcr_drug_barcode": "TCGA-HF-7136-D18757",
    "bcr_drug_uuid": "e9d48e7a-d2e8-4e88-954b-585b89d3750c",
    "form_completion_date": "2011-11-17",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "drug_cycles": 5,
    "drug_units": "MG/DAY",
    "drug_tota_dose_units": "MG",
    "drug_dose": 76,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION",
    "drug_total_dose": 421
  },
  {
    "bcr_patient_uuid": "647dc54f-a51b-40ea-9d97-c93598c2af71",
    "patient_ID": "TCGA.HF.7136",
    "bcr_drug_barcode": "TCGA-HF-7136-D18755",
    "bcr_drug_uuid": "bc726173-e095-4b8f-9532-0d24c32d00de",
    "form_completion_date": "2011-11-17",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "drug_cycles": 4,
    "drug_units": "MG/DAY",
    "drug_tota_dose_units": "MG",
    "drug_dose": 800,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 14100
  },
  {
    "bcr_patient_uuid": "647dc54f-a51b-40ea-9d97-c93598c2af71",
    "patient_ID": "TCGA.HF.7136",
    "bcr_drug_barcode": "TCGA-HF-7136-D18760",
    "bcr_drug_uuid": "385a379b-e305-47b1-aa71-4fc4c3fe1e63",
    "form_completion_date": "2011-11-17",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "drug_cycles": 5,
    "drug_units": "MG/DAY",
    "drug_tota_dose_units": "MG",
    "drug_dose": 90,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION",
    "drug_total_dose": 501
  },
  {
    "bcr_patient_uuid": "647dc54f-a51b-40ea-9d97-c93598c2af71",
    "patient_ID": "TCGA.HF.7136",
    "bcr_drug_barcode": "TCGA-HF-7136-D18759",
    "bcr_drug_uuid": "f1e59e77-bd39-4df4-b2c0-b689f6e77e91",
    "form_completion_date": "2011-11-17",
    "pharmaceutical_therapy_drug_name": "CEPECITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "drug_cycles": 5,
    "drug_units": "MG/DAY",
    "drug_tota_dose_units": "MG",
    "drug_dose": 1050,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION",
    "drug_total_dose": 5650
  },
  {
    "bcr_patient_uuid": "A58B6CD2-48F8-47D0-B97A-02A376F83E5C",
    "patient_ID": "TCGA.HF.A5NB",
    "bcr_drug_barcode": "TCGA-HF-A5NB-D49160",
    "bcr_drug_uuid": "03D7E595-62F0-4FAB-94D9-EDA14C9B93A8",
    "form_completion_date": "2013-9-26",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 77,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 207,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "83d681f4-6c0e-45cc-a31d-0b1b31c8e073",
    "patient_ID": "TCGA.HJ.7597",
    "bcr_drug_barcode": "TCGA-HJ-7597-D32547",
    "bcr_drug_uuid": "91F08499-C9F4-4179-977F-A1A96392F19B",
    "form_completion_date": "2012-5-31",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 296,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 471,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "83d681f4-6c0e-45cc-a31d-0b1b31c8e073",
    "patient_ID": "TCGA.HJ.7597",
    "bcr_drug_barcode": "TCGA-HJ-7597-D32549",
    "bcr_drug_uuid": "370C9E04-8F29-4DBD-B78D-2E2E01B3FD0B",
    "form_completion_date": "2012-5-31",
    "pharmaceutical_therapy_drug_name": "CAMPTOSAR",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 296,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 471,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "83d681f4-6c0e-45cc-a31d-0b1b31c8e073",
    "patient_ID": "TCGA.HJ.7597",
    "bcr_drug_barcode": "TCGA-HJ-7597-D32554",
    "bcr_drug_uuid": "6DDED852-7857-49FD-9A3B-BE565DE984C0",
    "form_completion_date": "2012-5-31",
    "pharmaceutical_therapy_drug_name": "METHOTREXATE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 793,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 795,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "ac77e22d-42c0-4e06-b904-0dd5b31eb0d8",
    "patient_ID": "TCGA.HU.8238",
    "bcr_drug_barcode": "TCGA-HU-8238-D42590",
    "bcr_drug_uuid": "0A1520C0-8375-43B2-B309-C50C377C8746",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "DIDOX",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 18,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 135,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "ac77e22d-42c0-4e06-b904-0dd5b31eb0d8",
    "patient_ID": "TCGA.HU.8238",
    "bcr_drug_barcode": "TCGA-HU-8238-D42589",
    "bcr_drug_uuid": "6E3EF210-089B-4D34-8A17-5A00781D8799",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "COPOLANG",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 18,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 75,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "77a8eab6-f6a1-4739-9031-75ead40d68cb",
    "patient_ID": "TCGA.HU.8243",
    "bcr_drug_barcode": "TCGA-HU-8243-D42415",
    "bcr_drug_uuid": "E3FC6226-824F-41AE-9FD2-B8468E8FF6BC",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 36,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 157,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "e302f643-eed3-4f07-a7fb-c32ee2031a1c",
    "patient_ID": "TCGA.HU.8249",
    "bcr_drug_barcode": "TCGA-HU-8249-D42416",
    "bcr_drug_uuid": "7F56CD5D-86E2-4D92-8925-DDCC98650C78",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 27,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 286,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "edce7aac-1d8b-41cb-88e2-f50b8eeca4d8",
    "patient_ID": "TCGA.HU.8602",
    "bcr_drug_barcode": "TCGA-HU-8602-D42417",
    "bcr_drug_uuid": "BA8CD6F4-CA91-4C9F-B1F3-E123F5013B46",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 30,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 154,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "43945bf6-6e64-4f13-9822-baf30dcd726c",
    "patient_ID": "TCGA.HU.8604",
    "bcr_drug_barcode": "TCGA-HU-8604-D42418",
    "bcr_drug_uuid": "BDF4B5C2-C206-4F16-B98D-1728FB3E5138",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "DOXIFLURIDINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 39,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "c6316fb5-99a7-4adf-832f-dce44ddcd3aa",
    "patient_ID": "TCGA.HU.8608",
    "bcr_drug_barcode": "TCGA-HU-8608-D42419",
    "bcr_drug_uuid": "0A77BA14-8825-4395-997A-A5BA7C780662",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "DOXIFLURIDINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 36,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3B17C66A-34AE-4B10-B907-4464D6D58383",
    "patient_ID": "TCGA.HU.A4G2",
    "bcr_drug_barcode": "TCGA-HU-A4G2-D42420",
    "bcr_drug_uuid": "C5FDCF48-F9DA-4500-9415-3FF441AB984A",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "DOXIFLURIDIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 28,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6EEEE564-1057-42E4-BFCE-B6FE17D58D10",
    "patient_ID": "TCGA.HU.A4G3",
    "bcr_drug_barcode": "TCGA-HU-A4G3-D42583",
    "bcr_drug_uuid": "AC5F6D07-2A0C-4D66-AC41-6CA7629E4A9F",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "MITOMYCIN C",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 20,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 97,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6EEEE564-1057-42E4-BFCE-B6FE17D58D10",
    "patient_ID": "TCGA.HU.A4G3",
    "bcr_drug_barcode": "TCGA-HU-A4G3-D42584",
    "bcr_drug_uuid": "85535BA0-CB53-4E72-AA93-66DA4FCF2273",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "DOXIFLURIDINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 111,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 184,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6EEEE564-1057-42E4-BFCE-B6FE17D58D10",
    "patient_ID": "TCGA.HU.A4G3",
    "bcr_drug_barcode": "TCGA-HU-A4G3-D42585",
    "bcr_drug_uuid": "22875D21-8B67-4CE0-B659-80AF69F5A06D",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "COPOLANG CAPS",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 111,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 184,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "16286EBD-6811-4E53-B4D5-82E1E825BC7A",
    "patient_ID": "TCGA.HU.A4G8",
    "bcr_drug_barcode": "TCGA-HU-A4G8-D42421",
    "bcr_drug_uuid": "56741153-A6E4-4BC8-91F2-EA8E0AC0D880",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 41,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AA88CE53-8439-40BD-8D93-E1D903D1C7FB",
    "patient_ID": "TCGA.HU.A4GD",
    "bcr_drug_barcode": "TCGA-HU-A4GD-D42586",
    "bcr_drug_uuid": "20650429-0759-41B3-BCA9-547FE96DD7FC",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "MICOMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 20,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 76,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AA88CE53-8439-40BD-8D93-E1D903D1C7FB",
    "patient_ID": "TCGA.HU.A4GD",
    "bcr_drug_barcode": "TCGA-HU-A4GD-D42587",
    "bcr_drug_uuid": "5DF77FF1-7DDB-40D9-A9C6-5F96966B4FE6",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "DOXIFLURIDINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 90,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 397,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AA88CE53-8439-40BD-8D93-E1D903D1C7FB",
    "patient_ID": "TCGA.HU.A4GD",
    "bcr_drug_barcode": "TCGA-HU-A4GD-D42588",
    "bcr_drug_uuid": "9424FF14-F579-4CF0-8D66-88E9105B1E8E",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "COPOLANG",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 90,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 381,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AA88CE53-8439-40BD-8D93-E1D903D1C7FB",
    "patient_ID": "TCGA.HU.A4GD",
    "bcr_drug_barcode": "TCGA-HU-A4GD-D42653",
    "bcr_drug_uuid": "07758E26-643E-46E4-AA92-5B17FC122DA6",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "ELOXATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 468,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AA88CE53-8439-40BD-8D93-E1D903D1C7FB",
    "patient_ID": "TCGA.HU.A4GD",
    "bcr_drug_barcode": "TCGA-HU-A4GD-D42654",
    "bcr_drug_uuid": "D36050A1-145A-4446-9352-8F7916DB47F4",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 468,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "05C4D180-A571-4ABB-BBDC-7363269DC0A6",
    "patient_ID": "TCGA.HU.A4GJ",
    "bcr_drug_barcode": "TCGA-HU-A4GJ-D42656",
    "bcr_drug_uuid": "BE11EE31-1399-4671-A094-92FCC165049F",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "TS-1",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 564,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 677,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "05C4D180-A571-4ABB-BBDC-7363269DC0A6",
    "patient_ID": "TCGA.HU.A4GJ",
    "bcr_drug_barcode": "TCGA-HU-A4GJ-D42655",
    "bcr_drug_uuid": "F6139820-C991-409B-B664-F52203E7A7E9",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 39,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 222,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "05C4D180-A571-4ABB-BBDC-7363269DC0A6",
    "patient_ID": "TCGA.HU.A4GJ",
    "bcr_drug_barcode": "TCGA-HU-A4GJ-D42591",
    "bcr_drug_uuid": "A166BF62-DB7E-4884-AFDF-7F3103766133",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 39,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 187,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F8A32CB0-8C3D-4BC2-8E53-561B89000BE7",
    "patient_ID": "TCGA.HU.A4GN",
    "bcr_drug_barcode": "TCGA-HU-A4GN-D42594",
    "bcr_drug_uuid": "47A48546-CB6A-4D81-871F-82E175DF3D42",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "COPOLANG",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 107,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 614,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F8A32CB0-8C3D-4BC2-8E53-561B89000BE7",
    "patient_ID": "TCGA.HU.A4GN",
    "bcr_drug_barcode": "TCGA-HU-A4GN-D42593",
    "bcr_drug_uuid": "426895CB-30C3-4D05-9A56-4E5CD847DAE8",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "DOXIFLURIDINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 107,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F8A32CB0-8C3D-4BC2-8E53-561B89000BE7",
    "patient_ID": "TCGA.HU.A4GN",
    "bcr_drug_barcode": "TCGA-HU-A4GN-D42592",
    "bcr_drug_uuid": "C18BBECB-2DA0-40E6-B8CD-1BEFB5195362",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "MITOMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 27,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 100,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "C46FF2BB-BDD0-48CD-B2AE-7EF421B4B91A",
    "patient_ID": "TCGA.HU.A4GP",
    "bcr_drug_barcode": "TCGA-HU-A4GP-D42595",
    "bcr_drug_uuid": "99F8A9B1-DC2D-4C3D-8786-9B67216B7F0A",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "DIDOX",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 70,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 362,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "C46FF2BB-BDD0-48CD-B2AE-7EF421B4B91A",
    "patient_ID": "TCGA.HU.A4GP",
    "bcr_drug_barcode": "TCGA-HU-A4GP-D42657",
    "bcr_drug_uuid": "4CC879C9-B013-45CD-A40F-695CB088FF37",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "COPOLANG",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 70,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 127,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "7997F3D8-BFF6-4808-8DF0-D88D344D7C9E",
    "patient_ID": "TCGA.HU.A4GT",
    "bcr_drug_barcode": "TCGA-HU-A4GT-D42596",
    "bcr_drug_uuid": "54482893-E7D3-4E62-B08B-66DECF08AAD1",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "COPOLANG",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 43,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 100,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "7997F3D8-BFF6-4808-8DF0-D88D344D7C9E",
    "patient_ID": "TCGA.HU.A4GT",
    "bcr_drug_barcode": "TCGA-HU-A4GT-D42597",
    "bcr_drug_uuid": "55D81573-576F-40C3-8F85-070D3733CECF",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "DIDOX",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 43,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 279,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "75915370-0895-4933-8875-8A31C65C3D50",
    "patient_ID": "TCGA.HU.A4GX",
    "bcr_drug_barcode": "TCGA-HU-A4GX-D42598",
    "bcr_drug_uuid": "8AC674A8-6EE9-438E-B986-8153087EDB30",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "TAXOL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 48,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 48,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "75915370-0895-4933-8875-8A31C65C3D50",
    "patient_ID": "TCGA.HU.A4GX",
    "bcr_drug_barcode": "TCGA-HU-A4GX-D42599",
    "bcr_drug_uuid": "DA2BC0A9-5B0F-41FB-B4CF-23F58CAE64C2",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "CDDP",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 48,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 48,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "39FA91BD-DFFD-4B2C-AF7D-7FD914730B08",
    "patient_ID": "TCGA.HU.A4H3",
    "bcr_drug_barcode": "TCGA-HU-A4H3-D41381",
    "bcr_drug_uuid": "824F83CB-92EE-4A46-B268-5F3AE38BC708",
    "form_completion_date": "2013-4-25",
    "pharmaceutical_therapy_drug_name": "TS-1",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 18,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 316,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "39FA91BD-DFFD-4B2C-AF7D-7FD914730B08",
    "patient_ID": "TCGA.HU.A4H3",
    "bcr_drug_barcode": "TCGA-HU-A4H3-D42338",
    "bcr_drug_uuid": "3182424B-B793-4C4A-AE9D-3417249B826E",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "XELODA(CAPECITABINE)",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 466,
    "pharmaceutical_tx_ongoing_indicator": true,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "39FA91BD-DFFD-4B2C-AF7D-7FD914730B08",
    "patient_ID": "TCGA.HU.A4H3",
    "bcr_drug_barcode": "TCGA-HU-A4H3-D42582",
    "bcr_drug_uuid": "36BD2379-DDA1-46E1-9ACC-4218A712E883",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "ELOXATIN(OXALIPLATIN)",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 466,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 666,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "00FDF96D-C48A-47E0-B91D-576C52E6819C",
    "patient_ID": "TCGA.HU.A4H4",
    "bcr_drug_barcode": "TCGA-HU-A4H4-D41382",
    "bcr_drug_uuid": "18B88DA0-0F13-4A38-AE5B-883CED6838BE",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "TS-1",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 13,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 309,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "D262FDF0-30BF-4618-9342-DE5A2A053828",
    "patient_ID": "TCGA.HU.A4H5",
    "bcr_drug_barcode": "TCGA-HU-A4H5-D42422",
    "bcr_drug_uuid": "4EB83C2F-169A-4534-836F-91A633638295",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "DOXIFLURIDINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 404,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "416FD59B-A4F8-4610-9F8B-473CB5C04A4A",
    "patient_ID": "TCGA.HU.A4H6",
    "bcr_drug_barcode": "TCGA-HU-A4H6-D42423",
    "bcr_drug_uuid": "4436467C-9121-4D9D-B804-539CEECB5E2E",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "DOXIFLURIDINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 42,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "98760B3E-3075-4444-9A01-8F11935069D4",
    "patient_ID": "TCGA.HU.A4H8",
    "bcr_drug_barcode": "TCGA-HU-A4H8-D42600",
    "bcr_drug_uuid": "641A776A-6E12-40C9-B22C-081EBECAC09D",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "DIDOX",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 18,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "36E36773-1D03-4ED0-AE31-1C0CA55577A4",
    "patient_ID": "TCGA.HU.A4HB",
    "bcr_drug_barcode": "TCGA-HU-A4HB-D42601",
    "bcr_drug_uuid": "9770C33F-ACC7-41CF-8867-219635F1627C",
    "form_completion_date": "2013-4-26",
    "pharmaceutical_therapy_drug_name": "TS-1",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 23,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "87c217d4-66f4-46ca-8244-7856ce658fd3",
    "patient_ID": "TCGA.IN.7806",
    "bcr_drug_barcode": "TCGA-IN-7806-D43603",
    "bcr_drug_uuid": "60ADFEE7-A33A-46E9-9FB5-1CED530F19A7",
    "form_completion_date": "2013-5-29",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 62,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 116,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "87c217d4-66f4-46ca-8244-7856ce658fd3",
    "patient_ID": "TCGA.IN.7806",
    "bcr_drug_barcode": "TCGA-IN-7806-D43604",
    "bcr_drug_uuid": "F45B2ED5-5FCE-4530-B895-7D4D6E34A528",
    "form_completion_date": "2013-5-29",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 62,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 116,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "87c217d4-66f4-46ca-8244-7856ce658fd3",
    "patient_ID": "TCGA.IN.7806",
    "bcr_drug_barcode": "TCGA-IN-7806-D43605",
    "bcr_drug_uuid": "935A544F-A6D0-41FB-90C0-8468319FE607",
    "form_completion_date": "2013-5-29",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 62,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 116,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "ba3911e6-2208-4a04-8891-b5cba9fda6bf",
    "patient_ID": "TCGA.IN.8462",
    "bcr_drug_barcode": "TCGA-IN-8462-D43597",
    "bcr_drug_uuid": "A446E68D-CCAA-4E68-99D0-F77E589DA83D",
    "form_completion_date": "2013-5-28",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 298,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 319,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "ba3911e6-2208-4a04-8891-b5cba9fda6bf",
    "patient_ID": "TCGA.IN.8462",
    "bcr_drug_barcode": "TCGA-IN-8462-D43598",
    "bcr_drug_uuid": "A2B28491-DEE4-4BE0-AA89-5A33194169A6",
    "form_completion_date": "2013-5-28",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 298,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 319,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "ba3911e6-2208-4a04-8891-b5cba9fda6bf",
    "patient_ID": "TCGA.IN.8462",
    "bcr_drug_barcode": "TCGA-IN-8462-D43599",
    "bcr_drug_uuid": "6D66C746-8C08-4507-9E95-68DAEB38BECD",
    "form_completion_date": "2013-5-28",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 298,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 319,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "ba3911e6-2208-4a04-8891-b5cba9fda6bf",
    "patient_ID": "TCGA.IN.8462",
    "bcr_drug_barcode": "TCGA-IN-8462-D43600",
    "bcr_drug_uuid": "84E86AF4-FD87-4366-91A2-3F755E33455A",
    "form_completion_date": "2013-5-28",
    "pharmaceutical_therapy_drug_name": "TAXOL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 427,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 540,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2AE1706B-C0F7-40E3-AFE5-CB75D1584B96",
    "patient_ID": "TCGA.IN.A6RO",
    "bcr_drug_barcode": "TCGA-IN-A6RO-D69484",
    "bcr_drug_uuid": "FF3388A1-C715-466B-B5D5-5723C3DA4DD0",
    "form_completion_date": "2015-1-9",
    "pharmaceutical_therapy_drug_name": "IRINOTECAN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 83,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 200,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2AE1706B-C0F7-40E3-AFE5-CB75D1584B96",
    "patient_ID": "TCGA.IN.A6RO",
    "bcr_drug_barcode": "TCGA-IN-A6RO-D69485",
    "bcr_drug_uuid": "BEB9ABBE-D8F1-4C12-AB2C-4E3E2BEEF2E0",
    "form_completion_date": "2015-1-9",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 83,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 200,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "DBC29B1B-42B8-4249-A1D1-3BA117EFEA43",
    "patient_ID": "TCGA.IN.A6RP",
    "bcr_drug_barcode": "TCGA-IN-A6RP-D57381",
    "bcr_drug_uuid": "60589C8E-4B78-4EBC-9458-E817FA9CA244",
    "form_completion_date": "2014-3-10",
    "pharmaceutical_therapy_drug_name": "IRINOTECAN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 79,
    "pharmaceutical_tx_ongoing_indicator": true,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "DBC29B1B-42B8-4249-A1D1-3BA117EFEA43",
    "patient_ID": "TCGA.IN.A6RP",
    "bcr_drug_barcode": "TCGA-IN-A6RP-D57382",
    "bcr_drug_uuid": "57DACD9C-C962-4EAF-BD41-E616BA1C8584",
    "form_completion_date": "2014-3-10",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 79,
    "pharmaceutical_tx_ongoing_indicator": true,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "7AB5A708-803F-4D8C-9B25-645F06851A26",
    "patient_ID": "TCGA.IN.A6RR",
    "bcr_drug_barcode": "TCGA-IN-A6RR-D61665",
    "bcr_drug_uuid": "E0A3FC19-7C10-4858-B595-1C83666E7A4E",
    "form_completion_date": "2014-7-2",
    "pharmaceutical_therapy_drug_name": "UNKOWN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 111,
    "pharmaceutical_tx_ongoing_indicator": false,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F74DF45F-8CFD-4DA8-BF84-7B1C80DC57EB",
    "patient_ID": "TCGA.IN.A7NR",
    "bcr_drug_barcode": "TCGA-IN-A7NR-D61523",
    "bcr_drug_uuid": "E0E8A4C0-1B89-4714-952E-19E00884D582",
    "form_completion_date": "2014-7-1",
    "pharmaceutical_therapy_drug_name": "CARBOPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 154,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F74DF45F-8CFD-4DA8-BF84-7B1C80DC57EB",
    "patient_ID": "TCGA.IN.A7NR",
    "bcr_drug_barcode": "TCGA-IN-A7NR-D61524",
    "bcr_drug_uuid": "145B1F23-DBF7-4CB6-81BD-BEE7E5C3D16B",
    "form_completion_date": "2014-7-1",
    "pharmaceutical_therapy_drug_name": "TAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 154,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "53108D62-6B7C-429F-9FEC-474781174968",
    "patient_ID": "TCGA.IN.A7NT",
    "bcr_drug_barcode": "TCGA-IN-A7NT-D57462",
    "bcr_drug_uuid": "ECB7FBBB-3573-4E30-80E3-28762A668E20",
    "form_completion_date": "2014-3-11",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 112,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "53108D62-6B7C-429F-9FEC-474781174968",
    "patient_ID": "TCGA.IN.A7NT",
    "bcr_drug_barcode": "TCGA-IN-A7NT-D61337",
    "bcr_drug_uuid": "F043E124-7B73-439D-8D5C-CE97FFBDEA6D",
    "form_completion_date": "2014-6-27",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 112,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "53108D62-6B7C-429F-9FEC-474781174968",
    "patient_ID": "TCGA.IN.A7NT",
    "bcr_drug_barcode": "TCGA-IN-A7NT-D61339",
    "bcr_drug_uuid": "DCCF82E6-7EDA-4C95-8EDF-175700F18198",
    "form_completion_date": "2014-6-27",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 112,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "26A5E389-8EC2-4316-BEEA-F9A63D455B73",
    "patient_ID": "TCGA.IN.A7NU",
    "bcr_drug_barcode": "TCGA-IN-A7NU-D69490",
    "bcr_drug_uuid": "73E895E5-F6C4-487C-BF05-61F3FFB8DB30",
    "form_completion_date": "2015-1-9",
    "pharmaceutical_therapy_drug_name": "TAXOL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 105,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 169,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "26A5E389-8EC2-4316-BEEA-F9A63D455B73",
    "patient_ID": "TCGA.IN.A7NU",
    "bcr_drug_barcode": "TCGA-IN-A7NU-D69491",
    "bcr_drug_uuid": "66407BB0-63A0-4D47-B62F-D1C05D098F9E",
    "form_completion_date": "2015-1-9",
    "pharmaceutical_therapy_drug_name": "CARBOPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 105,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 169,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1E5A3796-6249-4A91-9FC8-0C273E337F29",
    "patient_ID": "TCGA.IN.AB1X",
    "bcr_drug_barcode": "TCGA-IN-AB1X-D61527",
    "bcr_drug_uuid": "7036BFC0-D6C7-452A-BE03-8CF57856E717",
    "form_completion_date": "2014-7-1",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 104,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1E5A3796-6249-4A91-9FC8-0C273E337F29",
    "patient_ID": "TCGA.IN.AB1X",
    "bcr_drug_barcode": "TCGA-IN-AB1X-D61528",
    "bcr_drug_uuid": "481EDF4C-2204-4963-A636-7D0B28EFFD0B",
    "form_completion_date": "2014-7-1",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 104,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1E5A3796-6249-4A91-9FC8-0C273E337F29",
    "patient_ID": "TCGA.IN.AB1X",
    "bcr_drug_barcode": "TCGA-IN-AB1X-D61529",
    "bcr_drug_uuid": "54B837B9-AC1F-462F-892A-66A5767F25A6",
    "form_completion_date": "2014-7-1",
    "pharmaceutical_therapy_drug_name": "OXALOPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 104,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "197D01A5-321C-461E-9B45-B359288B959A",
    "patient_ID": "TCGA.KB.A6F7",
    "bcr_drug_barcode": "TCGA-KB-A6F7-D53982",
    "bcr_drug_uuid": "918103C9-472F-4799-B534-43AE1A9FCBF7",
    "form_completion_date": "2013-12-16",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 150,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 154,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5F263B2C-3385-4D07-99C2-D7B613C4A470",
    "patient_ID": "TCGA.KB.A93J",
    "bcr_drug_barcode": "TCGA-KB-A93J-D60968",
    "bcr_drug_uuid": "6DA4D2AD-66A5-4E91-9796-1ABECA4A3CFE",
    "form_completion_date": "2014-6-20",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 157,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 255,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "D04E2E8C-9D58-4514-8AB7-3642289D4DE0",
    "patient_ID": "TCGA.MX.A666",
    "bcr_drug_barcode": "TCGA-MX-A666-D61117",
    "bcr_drug_uuid": "F6F569B1-0554-470A-8DDE-0AD8A839EC11",
    "form_completion_date": "2014-6-24",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 22,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 22,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "D04E2E8C-9D58-4514-8AB7-3642289D4DE0",
    "patient_ID": "TCGA.MX.A666",
    "bcr_drug_barcode": "TCGA-MX-A666-D61118",
    "bcr_drug_uuid": "5F6546A3-D921-4E6A-85D8-89866B9D9827",
    "form_completion_date": "2014-6-24",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 22,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 22,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "D04E2E8C-9D58-4514-8AB7-3642289D4DE0",
    "patient_ID": "TCGA.MX.A666",
    "bcr_drug_barcode": "TCGA-MX-A666-D61119",
    "bcr_drug_uuid": "9433FAAF-66EA-44D6-9D23-E9B5C83C7633",
    "form_completion_date": "2014-6-24",
    "pharmaceutical_therapy_drug_name": "CAPECITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 22,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 22,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "D04E2E8C-9D58-4514-8AB7-3642289D4DE0",
    "patient_ID": "TCGA.MX.A666",
    "bcr_drug_barcode": "TCGA-MX-A666-D61120",
    "bcr_drug_uuid": "8041D0BE-7BC8-4D3B-96A7-A1EA8B8EE0EA",
    "form_completion_date": "2014-6-24",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 117,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 131,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "D04E2E8C-9D58-4514-8AB7-3642289D4DE0",
    "patient_ID": "TCGA.MX.A666",
    "bcr_drug_barcode": "TCGA-MX-A666-D61121",
    "bcr_drug_uuid": "CF6DE4EA-0F57-460D-A170-DEB48D99280B",
    "form_completion_date": "2014-6-24",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 117,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 131,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AA3D2D17-19E3-4B76-8235-98550F49DC91",
    "patient_ID": "TCGA.RD.A7BS",
    "bcr_drug_barcode": "TCGA-RD-A7BS-D56619",
    "bcr_drug_uuid": "1D674365-2868-4EC5-B273-CCF8CB678B03",
    "form_completion_date": "2014-2-16",
    "pharmaceutical_therapy_drug_name": "5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 74,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 104,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "B54FE07A-F63D-4861-878A-8E8322E32FED",
    "patient_ID": "TCGA.RD.A7BW",
    "bcr_drug_barcode": "TCGA-RD-A7BW-D56636",
    "bcr_drug_uuid": "4D7D4678-00EC-4BE4-B5DD-7EDF38A98397",
    "form_completion_date": "2014-2-16",
    "pharmaceutical_therapy_drug_name": "5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 49,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 124,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "B54FE07A-F63D-4861-878A-8E8322E32FED",
    "patient_ID": "TCGA.RD.A7BW",
    "bcr_drug_barcode": "TCGA-RD-A7BW-D56638",
    "bcr_drug_uuid": "D7476D03-9828-4485-AA40-446B8916495B",
    "form_completion_date": "2014-2-16",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 49,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 49,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "B54FE07A-F63D-4861-878A-8E8322E32FED",
    "patient_ID": "TCGA.RD.A7BW",
    "bcr_drug_barcode": "TCGA-RD-A7BW-D56639",
    "bcr_drug_uuid": "FA492B70-B82D-41BF-B606-E58BDDD9B4CE",
    "form_completion_date": "2014-2-16",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 49,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 49,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "17638F77-3D0A-4B7F-8801-D807AAD6BBD4",
    "patient_ID": "TCGA.RD.A8MV",
    "bcr_drug_barcode": "TCGA-RD-A8MV-D57261",
    "bcr_drug_uuid": "64B260D2-E38F-4078-875C-42E56261B24C",
    "form_completion_date": "2014-3-7",
    "pharmaceutical_therapy_drug_name": "5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 50,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 186,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "17638F77-3D0A-4B7F-8801-D807AAD6BBD4",
    "patient_ID": "TCGA.RD.A8MV",
    "bcr_drug_barcode": "TCGA-RD-A8MV-D57262",
    "bcr_drug_uuid": "AB9CFB7F-D858-448E-9F69-F426B91ABBBB",
    "form_completion_date": "2014-3-7",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 50,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 50,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "17638F77-3D0A-4B7F-8801-D807AAD6BBD4",
    "patient_ID": "TCGA.RD.A8MV",
    "bcr_drug_barcode": "TCGA-RD-A8MV-D57263",
    "bcr_drug_uuid": "B5F4B736-9D64-44BC-B4DE-A39D5FEB3298",
    "form_completion_date": "2014-3-7",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 50,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 50,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0B787BDB-949D-499C-AECE-7A3977FCD198",
    "patient_ID": "TCGA.RD.A8MW",
    "bcr_drug_barcode": "TCGA-RD-A8MW-D57389",
    "bcr_drug_uuid": "06FF3B8D-396B-4948-9134-9997849CB85C",
    "form_completion_date": "2014-3-10",
    "pharmaceutical_therapy_drug_name": "5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 69,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 96,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2360C1E2-90F5-4737-9486-3F4590C37322",
    "patient_ID": "TCGA.RD.A8N0",
    "bcr_drug_barcode": "TCGA-RD-A8N0-D57397",
    "bcr_drug_uuid": "AA7457EC-1BB2-45D5-A83A-538089EF1A1F",
    "form_completion_date": "2014-3-10",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 64,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 64,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2360C1E2-90F5-4737-9486-3F4590C37322",
    "patient_ID": "TCGA.RD.A8N0",
    "bcr_drug_barcode": "TCGA-RD-A8N0-D57398",
    "bcr_drug_uuid": "51EAECCB-B1A8-45C0-B136-030CEF61EEA7",
    "form_completion_date": "2014-3-10",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 64,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 64,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2360C1E2-90F5-4737-9486-3F4590C37322",
    "patient_ID": "TCGA.RD.A8N0",
    "bcr_drug_barcode": "TCGA-RD-A8N0-D57399",
    "bcr_drug_uuid": "20F89BF8-7551-4683-ABB8-6301CCD2154B",
    "form_completion_date": "2014-3-10",
    "pharmaceutical_therapy_drug_name": "5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 64,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 123,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "46D7489A-CFE6-440E-9D50-919D0EAD8018",
    "patient_ID": "TCGA.RD.A8N1",
    "bcr_drug_barcode": "TCGA-RD-A8N1-D57471",
    "bcr_drug_uuid": "E2E5C483-E96D-426E-ACFB-5B62999EC26E",
    "form_completion_date": "2014-3-11",
    "pharmaceutical_therapy_drug_name": "5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 75,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 211,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "26BBEAFA-6923-4C23-8D5F-AA33FBA92E82",
    "patient_ID": "TCGA.RD.A8N4",
    "bcr_drug_barcode": "TCGA-RD-A8N4-D57478",
    "bcr_drug_uuid": "6EA47B35-DDFE-4159-89B5-060C18B3E70C",
    "form_completion_date": "2014-3-11",
    "pharmaceutical_therapy_drug_name": "5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 49,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 189,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "26BBEAFA-6923-4C23-8D5F-AA33FBA92E82",
    "patient_ID": "TCGA.RD.A8N4",
    "bcr_drug_barcode": "TCGA-RD-A8N4-D57479",
    "bcr_drug_uuid": "8C7B5B76-A6C2-4BED-9AED-2CCC8AD94B5C",
    "form_completion_date": "2014-3-11",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 49,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 49,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "26BBEAFA-6923-4C23-8D5F-AA33FBA92E82",
    "patient_ID": "TCGA.RD.A8N4",
    "bcr_drug_barcode": "TCGA-RD-A8N4-D57480",
    "bcr_drug_uuid": "7193209A-BBB6-4FC0-8187-8F75060C784B",
    "form_completion_date": "2014-3-11",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 49,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 49,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6E2ECC9D-DC68-4922-A36E-E8BBAF9EAFB3",
    "patient_ID": "TCGA.RD.A8N5",
    "bcr_drug_barcode": "TCGA-RD-A8N5-D57482",
    "bcr_drug_uuid": "6C0882D6-B18C-4933-A69B-6F7A32CB8237",
    "form_completion_date": "2014-3-11",
    "pharmaceutical_therapy_drug_name": "5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 82,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 209,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8CE63594-BF4A-4B8D-9A48-49CB92B98EA9",
    "patient_ID": "TCGA.RD.A8N9",
    "bcr_drug_barcode": "TCGA-RD-A8N9-D57485",
    "bcr_drug_uuid": "D10D7F84-10D2-4841-B309-0D5EB2AC45D6",
    "form_completion_date": "2014-3-12",
    "pharmaceutical_therapy_drug_name": "5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 136,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 239,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8CE63594-BF4A-4B8D-9A48-49CB92B98EA9",
    "patient_ID": "TCGA.RD.A8N9",
    "bcr_drug_barcode": "TCGA-RD-A8N9-D57514",
    "bcr_drug_uuid": "CE0E7D2B-FD82-4D99-A22C-5336863B48DE",
    "form_completion_date": "2014-3-12",
    "pharmaceutical_therapy_drug_name": "EPIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 105,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 225,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8CE63594-BF4A-4B8D-9A48-49CB92B98EA9",
    "patient_ID": "TCGA.RD.A8N9",
    "bcr_drug_barcode": "TCGA-RD-A8N9-D57516",
    "bcr_drug_uuid": "5076D26C-551F-4153-AA1B-91469A7B56CE",
    "form_completion_date": "2014-3-12",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 105,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 225,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BFDCC333-1B9D-44D2-90A4-C1720BA712E9",
    "patient_ID": "TCGA.SW.A7EB",
    "bcr_drug_barcode": "TCGA-SW-A7EB-D56024",
    "bcr_drug_uuid": "9537E9B4-12CC-4C88-958D-BDD3EA6D731B",
    "form_completion_date": "2014-1-25",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 28,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 35,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BFDCC333-1B9D-44D2-90A4-C1720BA712E9",
    "patient_ID": "TCGA.SW.A7EB",
    "bcr_drug_barcode": "TCGA-SW-A7EB-D56025",
    "bcr_drug_uuid": "E144DD9C-E3F1-4829-913B-50D8BC142A35",
    "form_completion_date": "2014-1-25",
    "pharmaceutical_therapy_drug_name": "DOXORUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 28,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 35,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BFDCC333-1B9D-44D2-90A4-C1720BA712E9",
    "patient_ID": "TCGA.SW.A7EB",
    "bcr_drug_barcode": "TCGA-SW-A7EB-D56026",
    "bcr_drug_uuid": "103EB591-19F6-4513-9C8B-827AFB26479C",
    "form_completion_date": "2014-1-25",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 28,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 35,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BFDCC333-1B9D-44D2-90A4-C1720BA712E9",
    "patient_ID": "TCGA.SW.A7EB",
    "bcr_drug_barcode": "TCGA-SW-A7EB-D56027",
    "bcr_drug_uuid": "DD4BCA11-AB99-4B38-AEE3-4D1663F1D9FB",
    "form_completion_date": "2014-1-25",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 64,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 70,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BFDCC333-1B9D-44D2-90A4-C1720BA712E9",
    "patient_ID": "TCGA.SW.A7EB",
    "bcr_drug_barcode": "TCGA-SW-A7EB-D56028",
    "bcr_drug_uuid": "A7CD5CC5-D770-4116-A896-AC30DB749220",
    "form_completion_date": "2014-1-25",
    "pharmaceutical_therapy_drug_name": "DOXORUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 64,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 70,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BFDCC333-1B9D-44D2-90A4-C1720BA712E9",
    "patient_ID": "TCGA.SW.A7EB",
    "bcr_drug_barcode": "TCGA-SW-A7EB-D56029",
    "bcr_drug_uuid": "9AB7E907-6432-4B21-BD00-A9B54C75D9B2",
    "form_completion_date": "2014-1-25",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 64,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 70,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BFDCC333-1B9D-44D2-90A4-C1720BA712E9",
    "patient_ID": "TCGA.SW.A7EB",
    "bcr_drug_barcode": "TCGA-SW-A7EB-D56030",
    "bcr_drug_uuid": "C9F32FDA-F421-4527-902A-4ABB77F4ACDD",
    "form_completion_date": "2014-1-25",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 101,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 106,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BFDCC333-1B9D-44D2-90A4-C1720BA712E9",
    "patient_ID": "TCGA.SW.A7EB",
    "bcr_drug_barcode": "TCGA-SW-A7EB-D56031",
    "bcr_drug_uuid": "9C70D3A7-938A-48BA-A737-C21F70D4284E",
    "form_completion_date": "2014-1-25",
    "pharmaceutical_therapy_drug_name": "DOXORUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 101,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 106,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BFDCC333-1B9D-44D2-90A4-C1720BA712E9",
    "patient_ID": "TCGA.SW.A7EB",
    "bcr_drug_barcode": "TCGA-SW-A7EB-D56032",
    "bcr_drug_uuid": "5AB31E67-4DC4-4DD8-A7C3-0773F438D310",
    "form_completion_date": "2014-1-25",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 101,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 106,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BFDCC333-1B9D-44D2-90A4-C1720BA712E9",
    "patient_ID": "TCGA.SW.A7EB",
    "bcr_drug_barcode": "TCGA-SW-A7EB-D56033",
    "bcr_drug_uuid": "8BE1D762-19E4-4265-8DE6-427F23A9BCD6",
    "form_completion_date": "2014-1-25",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 136,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 141,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BFDCC333-1B9D-44D2-90A4-C1720BA712E9",
    "patient_ID": "TCGA.SW.A7EB",
    "bcr_drug_barcode": "TCGA-SW-A7EB-D56034",
    "bcr_drug_uuid": "9B3B6E87-EB4B-4AC5-AAEF-F8062393C748",
    "form_completion_date": "2014-1-25",
    "pharmaceutical_therapy_drug_name": "DOXORUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 136,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 141,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BFDCC333-1B9D-44D2-90A4-C1720BA712E9",
    "patient_ID": "TCGA.SW.A7EB",
    "bcr_drug_barcode": "TCGA-SW-A7EB-D56035",
    "bcr_drug_uuid": "DAE012FB-2F68-4F22-AC83-0C1BEEBAA327",
    "form_completion_date": "2014-1-25",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 136,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 141,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8027ADC9-4918-45F0-A7DA-5767DA0B999E",
    "patient_ID": "TCGA.VQ.A8DT",
    "bcr_drug_barcode": "TCGA-VQ-A8DT-D64317",
    "bcr_drug_uuid": "4E65A83C-270A-4A8C-98AF-560BE8C8534C",
    "form_completion_date": "2014-8-28",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 94,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 222,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6FA6ACE1-4B39-44DB-9413-73EB21588AA1",
    "patient_ID": "TCGA.VQ.A8DU",
    "bcr_drug_barcode": "TCGA-VQ-A8DU-D64319",
    "bcr_drug_uuid": "E2E1E597-3757-4066-8D2F-AEB723369B31",
    "form_completion_date": "2014-8-28",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 130,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 130,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "A8A9B061-B33C-4C69-BD4C-7F430474CDFD",
    "patient_ID": "TCGA.VQ.A8DZ",
    "bcr_drug_barcode": "TCGA-VQ-A8DZ-D64321",
    "bcr_drug_uuid": "81F636F1-DE6B-45C1-87C8-9011394A5341",
    "form_completion_date": "2014-8-28",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 201,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 341,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "EB9A558C-39EF-42C0-8DFC-64D01B729426",
    "patient_ID": "TCGA.VQ.A8E0",
    "bcr_drug_barcode": "TCGA-VQ-A8E0-D64680",
    "bcr_drug_uuid": "5F7FF237-739E-4B57-84A3-046625B24DA0",
    "form_completion_date": "2014-9-9",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "C16EED96-8DA8-4D01-B87D-660F46172777",
    "patient_ID": "TCGA.VQ.A8E2",
    "bcr_drug_barcode": "TCGA-VQ-A8E2-D64324",
    "bcr_drug_uuid": "A5F2A67A-C50A-4FA4-AF85-EE0426650DE7",
    "form_completion_date": "2014-8-28",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 145,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 277,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "A0D35A25-3500-46F3-874F-1A0820200473",
    "patient_ID": "TCGA.VQ.A8P2",
    "bcr_drug_barcode": "TCGA-VQ-A8P2-D64331",
    "bcr_drug_uuid": "31794DDC-9E61-4210-9C6D-3F4A79A87CD0",
    "form_completion_date": "2014-8-28",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 107,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5C68E3E4-58F7-4699-989D-80D2E4996794",
    "patient_ID": "TCGA.VQ.A8P3",
    "bcr_drug_barcode": "TCGA-VQ-A8P3-D64335",
    "bcr_drug_uuid": "C18D0623-C8DB-4FCD-A983-6DAFF2074744",
    "form_completion_date": "2014-8-28",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 124,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 254,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1654C42B-664B-407E-8CA7-D4CD908B709A",
    "patient_ID": "TCGA.VQ.A8P5",
    "bcr_drug_barcode": "TCGA-VQ-A8P5-D64338",
    "bcr_drug_uuid": "514FB4F7-8748-45DD-892A-5384FB216EBC",
    "form_completion_date": "2014-8-28",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 115,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 213,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "02661985-D13F-4007-9A42-5E08D1A6CA10",
    "patient_ID": "TCGA.VQ.A8PB",
    "bcr_drug_barcode": "TCGA-VQ-A8PB-D64339",
    "bcr_drug_uuid": "D5460FEE-2114-400B-A562-20B3220DCE89",
    "form_completion_date": "2014-8-28",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 63,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 273,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "76DF6303-A635-410B-A4D9-DB5DCE72FCBC",
    "patient_ID": "TCGA.VQ.A8PD",
    "bcr_drug_barcode": "TCGA-VQ-A8PD-D64343",
    "bcr_drug_uuid": "1F2B1403-26D0-485E-8B91-D5B2A3BBE0DD",
    "form_completion_date": "2014-8-29",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 117,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 121,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "E181474C-1585-4AED-BA90-BAE5324569D5",
    "patient_ID": "TCGA.VQ.A8PP",
    "bcr_drug_barcode": "TCGA-VQ-A8PP-D64347",
    "bcr_drug_uuid": "F22052EF-BC6D-43DA-8C42-4EFA26744DF3",
    "form_completion_date": "2014-8-29",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 165,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 333,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5C1AFB64-DA74-4D2C-8BE3-E6C21D2952A9",
    "patient_ID": "TCGA.VQ.A8PT",
    "bcr_drug_barcode": "TCGA-VQ-A8PT-D64353",
    "bcr_drug_uuid": "098B323A-0B39-48E9-96A2-EAE6950695C1",
    "form_completion_date": "2014-8-29",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 193,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 197,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5C1AFB64-DA74-4D2C-8BE3-E6C21D2952A9",
    "patient_ID": "TCGA.VQ.A8PT",
    "bcr_drug_barcode": "TCGA-VQ-A8PT-D64354",
    "bcr_drug_uuid": "3EE08022-2343-48AC-928A-CE9768F8A27E",
    "form_completion_date": "2014-8-29",
    "pharmaceutical_therapy_drug_name": "XELOX",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 221,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 263,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "CB4394EC-1991-460D-B823-B74E005E3DA7",
    "patient_ID": "TCGA.VQ.A8PU",
    "bcr_drug_barcode": "TCGA-VQ-A8PU-D64696",
    "bcr_drug_uuid": "C426D913-C9BD-4C61-AB68-1878AFB6B6F1",
    "form_completion_date": "2014-9-9",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 139,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 288,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AC359B60-1977-4AA9-99D3-8D17D7D66E11",
    "patient_ID": "TCGA.VQ.A8PY",
    "bcr_drug_barcode": "TCGA-VQ-A8PY-D64358",
    "bcr_drug_uuid": "E2D0DF33-C876-4C1C-BEB5-5AFE512111CB",
    "form_completion_date": "2014-8-29",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 54,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 192,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "91C94A0D-F088-40E6-A4B1-D2A72AD35077",
    "patient_ID": "TCGA.VQ.A8PZ",
    "bcr_drug_barcode": "TCGA-VQ-A8PZ-D64363",
    "bcr_drug_uuid": "6367C026-7AF2-4BFE-91CE-A39993B8FDD5",
    "form_completion_date": "2014-8-29",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 121,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 234,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "33A9F48E-75E5-4EC5-8E4A-7C6D91A98656",
    "patient_ID": "TCGA.VQ.A91D",
    "bcr_drug_barcode": "TCGA-VQ-A91D-D64677",
    "bcr_drug_uuid": "11C87F76-33D3-4962-800E-13276D39684F",
    "form_completion_date": "2014-9-9",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 147,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 242,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2E04B48C-0805-4965-8AFA-C5FCD32993C5",
    "patient_ID": "TCGA.VQ.A91E",
    "bcr_drug_barcode": "TCGA-VQ-A91E-D64374",
    "bcr_drug_uuid": "8DC05F0E-3518-41BC-916D-6AE3A1CAE36C",
    "form_completion_date": "2014-8-29",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 59,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 59,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2983F08C-3B32-4FB3-9D7E-5B34F9C2F741",
    "patient_ID": "TCGA.VQ.A91K",
    "bcr_drug_barcode": "TCGA-VQ-A91K-D64377",
    "bcr_drug_uuid": "B474ED84-E71A-4546-B8C4-4DF74D7D0352",
    "form_completion_date": "2014-8-29",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 89,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 234,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "CBE05333-3185-4878-B6E6-977A0E1400E4",
    "patient_ID": "TCGA.VQ.A91N",
    "bcr_drug_barcode": "TCGA-VQ-A91N-D66745",
    "bcr_drug_uuid": "159F25A1-0142-455B-A134-A89B2C4BC995",
    "form_completion_date": "2014-10-23",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 98,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 219,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "C60E89A7-A8BA-458E-8F10-785C3F562FD6",
    "patient_ID": "TCGA.VQ.A91Q",
    "bcr_drug_barcode": "TCGA-VQ-A91Q-D64382",
    "bcr_drug_uuid": "91421FCF-D5D9-4AF6-B476-31DE5F8DCCF1",
    "form_completion_date": "2014-8-29",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 158,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 311,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "D22DE643-5F93-42D0-9199-1F55405241D6",
    "patient_ID": "TCGA.VQ.A91S",
    "bcr_drug_barcode": "TCGA-VQ-A91S-D65299",
    "bcr_drug_uuid": "81AAF0DA-6506-45FB-8B3C-84257778CBD3",
    "form_completion_date": "2014-9-21",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 122,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 238,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4A00CA75-D23A-4642-BEE8-DB4182517724",
    "patient_ID": "TCGA.VQ.A91V",
    "bcr_drug_barcode": "TCGA-VQ-A91V-D64685",
    "bcr_drug_uuid": "51E9B0EE-C954-42A8-9405-A956314733F2",
    "form_completion_date": "2014-9-9",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 77,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 228,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4A00CA75-D23A-4642-BEE8-DB4182517724",
    "patient_ID": "TCGA.VQ.A91V",
    "bcr_drug_barcode": "TCGA-VQ-A91V-D64686",
    "bcr_drug_uuid": "D10959BE-23EE-4949-9566-C88A298F0369",
    "form_completion_date": "2014-9-9",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 77,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 228,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "7861DCA2-BADC-4575-A388-621D3614A8E4",
    "patient_ID": "TCGA.VQ.A91W",
    "bcr_drug_barcode": "TCGA-VQ-A91W-D64384",
    "bcr_drug_uuid": "482DA894-9EEF-4A33-9B3B-5A9D9FAF50A1",
    "form_completion_date": "2014-8-29",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 87,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 217,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "807BEA1D-975A-4D01-98C5-2748D832235B",
    "patient_ID": "TCGA.VQ.A91Y",
    "bcr_drug_barcode": "TCGA-VQ-A91Y-D64390",
    "bcr_drug_uuid": "3B7E868F-35CF-4044-AB80-ABFD27FF0316",
    "form_completion_date": "2014-8-29",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 84,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 237,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "CAFBAE18-12A5-40FB-9DBE-C1D0598B9091",
    "patient_ID": "TCGA.VQ.A91Z",
    "bcr_drug_barcode": "TCGA-VQ-A91Z-D67233",
    "bcr_drug_uuid": "9B48A985-B662-403D-A6CD-9FB498AB278F",
    "form_completion_date": "2014-11-3",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 97,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 322,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "CAFBAE18-12A5-40FB-9DBE-C1D0598B9091",
    "patient_ID": "TCGA.VQ.A91Z",
    "bcr_drug_barcode": "TCGA-VQ-A91Z-D67234",
    "bcr_drug_uuid": "78598CD3-2552-407A-A6D7-5D6D29F0F92E",
    "form_completion_date": "2014-11-3",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 97,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 322,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8BD783A3-D6C9-4C87-A2A1-09F903B9C7CA",
    "patient_ID": "TCGA.VQ.A922",
    "bcr_drug_barcode": "TCGA-VQ-A922-D64400",
    "bcr_drug_uuid": "6A9F4DBF-C49F-4FE0-9C09-19EC8CC2F732",
    "form_completion_date": "2014-8-29",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 83,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 85,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "43B7A790-35A2-4786-B375-C3847D2AEC62",
    "patient_ID": "TCGA.VQ.A928",
    "bcr_drug_barcode": "TCGA-VQ-A928-D64403",
    "bcr_drug_uuid": "0ED28588-E3E5-4F96-8A42-5252CB038C0B",
    "form_completion_date": "2014-8-29",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 98,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 138,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "E12D142E-7339-48FC-B17A-9E311B65327F",
    "patient_ID": "TCGA.VQ.A94O",
    "bcr_drug_barcode": "TCGA-VQ-A94O-D64672",
    "bcr_drug_uuid": "524E53E4-6434-4F21-9C5E-9D701A56E6F3",
    "form_completion_date": "2014-9-9",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 200,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 392,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "95EDFABE-0B35-4CDD-AED4-E2234D806F35",
    "patient_ID": "TCGA.VQ.A94R",
    "bcr_drug_barcode": "TCGA-VQ-A94R-D64670",
    "bcr_drug_uuid": "75810C15-1476-4192-9D27-164BDB5FF842",
    "form_completion_date": "2014-9-9",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 591,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 645,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "FB143117-C3AD-4F4B-8F39-7586279E8EAA",
    "patient_ID": "TCGA.VQ.AA64",
    "bcr_drug_barcode": "TCGA-VQ-AA64-D64673",
    "bcr_drug_uuid": "B6EE592E-F365-4CB9-9AB4-A2BC1D21D202",
    "form_completion_date": "2014-9-9",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 73,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 192,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3FF9B46B-325F-4655-AB40-953154753DAE",
    "patient_ID": "TCGA.VQ.AA68",
    "bcr_drug_barcode": "TCGA-VQ-AA68-D64702",
    "bcr_drug_uuid": "F3DDCC61-8947-4F46-94EF-40384F945D2E",
    "form_completion_date": "2014-9-9",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 152,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 324,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "40CB6F49-3D68-45DC-9BFA-B4D724DE7DFE",
    "patient_ID": "TCGA.VQ.AA6B",
    "bcr_drug_barcode": "TCGA-VQ-AA6B-D64669",
    "bcr_drug_uuid": "71291602-C996-44B8-9751-2F16D0F9FCF9",
    "form_completion_date": "2014-9-9",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 131,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 262,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5779F7A7-05D7-4972-BD4F-AACB32420510",
    "patient_ID": "TCGA.VQ.AA6D",
    "bcr_drug_barcode": "TCGA-VQ-AA6D-D64666",
    "bcr_drug_uuid": "ACF2E282-F57B-4B12-AB29-082AE46A2AA2",
    "form_completion_date": "2014-9-9",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 77,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 114,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "DCCD3854-8865-4452-9F1C-97283509B553",
    "patient_ID": "TCGA.VQ.AA6F",
    "bcr_drug_barcode": "TCGA-VQ-AA6F-D64682",
    "bcr_drug_uuid": "B2EBE675-9B97-4D60-8383-A8ABD5F954F8",
    "form_completion_date": "2014-9-9",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 119,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 249,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "A3F03A0A-F251-4588-97BC-3403597A35AD",
    "patient_ID": "TCGA.VQ.AA6G",
    "bcr_drug_barcode": "TCGA-VQ-AA6G-D64691",
    "bcr_drug_uuid": "2A41B04D-9375-48C1-8043-9F44FD0E8B08",
    "form_completion_date": "2014-9-9",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 171,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 297,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3CCBE7C7-C779-4A98-B495-FF020D3E9E55",
    "patient_ID": "TCGA.VQ.AA6I",
    "bcr_drug_barcode": "TCGA-VQ-AA6I-D64658",
    "bcr_drug_uuid": "FACF827A-A698-4023-936B-84131CD34022",
    "form_completion_date": "2014-9-9",
    "pharmaceutical_therapy_drug_name": "XELOX",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 133,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 349,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "83A0F9EF-4BF0-4EFE-8713-F8B6AB4F5773",
    "patient_ID": "TCGA.VQ.AA6K",
    "bcr_drug_barcode": "TCGA-VQ-AA6K-D64660",
    "bcr_drug_uuid": "29547B3E-086E-46B1-9D0B-A81674996103",
    "form_completion_date": "2014-9-9",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 136,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 280,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  }
]
